WO2011072207A1 - Inhibiteurs azocycliques de l'hydrolase des amides d'acides gras - Google Patents
Inhibiteurs azocycliques de l'hydrolase des amides d'acides gras Download PDFInfo
- Publication number
- WO2011072207A1 WO2011072207A1 PCT/US2010/059850 US2010059850W WO2011072207A1 WO 2011072207 A1 WO2011072207 A1 WO 2011072207A1 US 2010059850 W US2010059850 W US 2010059850W WO 2011072207 A1 WO2011072207 A1 WO 2011072207A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- haloalkyl
- independently selected
- phenyl
- optionally substituted
- Prior art date
Links
- 108010046094 fatty-acid amide hydrolase Proteins 0.000 title claims abstract description 35
- 102100029111 Fatty-acid amide hydrolase 1 Human genes 0.000 title claims abstract description 34
- 239000003112 inhibitor Substances 0.000 title claims description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 245
- 238000000034 method Methods 0.000 claims abstract description 111
- 150000003839 salts Chemical class 0.000 claims abstract description 67
- 230000000694 effects Effects 0.000 claims abstract description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
- -1 cyano, hydroxy Chemical group 0.000 claims description 216
- 125000000217 alkyl group Chemical group 0.000 claims description 108
- 125000001424 substituent group Chemical group 0.000 claims description 98
- 125000001188 haloalkyl group Chemical group 0.000 claims description 84
- 208000002193 Pain Diseases 0.000 claims description 64
- 229910052736 halogen Inorganic materials 0.000 claims description 60
- 150000002367 halogens Chemical group 0.000 claims description 59
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 57
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 50
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 49
- 125000004432 carbon atom Chemical group C* 0.000 claims description 47
- 230000036407 pain Effects 0.000 claims description 47
- 125000003545 alkoxy group Chemical group 0.000 claims description 41
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 31
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 28
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 26
- 125000004995 haloalkylthio group Chemical group 0.000 claims description 26
- 150000001204 N-oxides Chemical class 0.000 claims description 24
- 125000004414 alkyl thio group Chemical group 0.000 claims description 23
- 125000004441 haloalkylsulfonyl group Chemical group 0.000 claims description 22
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 20
- 125000005842 heteroatom Chemical group 0.000 claims description 20
- 229910052760 oxygen Inorganic materials 0.000 claims description 20
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 19
- 229910052717 sulfur Inorganic materials 0.000 claims description 18
- 229910052799 carbon Inorganic materials 0.000 claims description 17
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 17
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 16
- 125000004429 atom Chemical group 0.000 claims description 15
- 229910052757 nitrogen Inorganic materials 0.000 claims description 15
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 14
- 125000005347 halocycloalkyl group Chemical group 0.000 claims description 14
- 125000001072 heteroaryl group Chemical group 0.000 claims description 14
- 125000001624 naphthyl group Chemical group 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 14
- 125000004771 (C1-C4) haloalkylsulfinyl group Chemical group 0.000 claims description 13
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 13
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 claims description 13
- 125000000262 haloalkenyl group Chemical group 0.000 claims description 13
- 125000000232 haloalkynyl group Chemical group 0.000 claims description 13
- 125000003282 alkyl amino group Chemical group 0.000 claims description 12
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims description 12
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 12
- 125000004076 pyridyl group Chemical group 0.000 claims description 12
- 125000001544 thienyl group Chemical group 0.000 claims description 12
- 125000004434 sulfur atom Chemical group 0.000 claims description 11
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 10
- 125000004692 haloalkylcarbonyl group Chemical group 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 10
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 8
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims description 8
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 7
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 7
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 125000005081 alkoxyalkoxyalkyl group Chemical group 0.000 claims description 6
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims description 6
- 125000005130 alkyl carbonyl thio group Chemical group 0.000 claims description 6
- 125000006350 alkyl thio alkyl group Chemical group 0.000 claims description 6
- 125000004858 cycloalkoxyalkyl group Chemical group 0.000 claims description 6
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 6
- 125000002883 imidazolyl group Chemical group 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 6
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 6
- 125000001425 triazolyl group Chemical group 0.000 claims description 6
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 5
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 claims description 5
- 125000006677 (C1-C3) haloalkoxy group Chemical group 0.000 claims description 5
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 5
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims description 5
- 125000004688 alkyl sulfonyl alkyl group Chemical group 0.000 claims description 5
- 125000000304 alkynyl group Chemical group 0.000 claims description 5
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims description 5
- NCZZHJPXIOTLEV-UHFFFAOYSA-N phenyl 4-[4-(5-phenyl-4,5-dihydro-1,2-oxazol-3-yl)-1,3-thiazol-2-yl]piperidine-1-carboxylate Chemical compound C1CC(C=2SC=C(N=2)C=2CC(ON=2)C=2C=CC=CC=2)CCN1C(=O)OC1=CC=CC=C1 NCZZHJPXIOTLEV-UHFFFAOYSA-N 0.000 claims description 5
- 125000004665 trialkylsilyl group Chemical group 0.000 claims description 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 4
- 125000004687 alkyl sulfinyl alkyl group Chemical group 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000004994 halo alkoxy alkyl group Chemical group 0.000 claims description 4
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- DZPNHXSCIKSDIE-UHFFFAOYSA-N (2-chlorophenyl) 4-[4-(5-phenyl-4,5-dihydro-1,2-oxazol-3-yl)-1,3-thiazol-2-yl]piperidine-1-carboxylate Chemical compound ClC1=CC=CC=C1OC(=O)N1CCC(C=2SC=C(N=2)C=2CC(ON=2)C=2C=CC=CC=2)CC1 DZPNHXSCIKSDIE-UHFFFAOYSA-N 0.000 claims 2
- 239000000203 mixture Substances 0.000 abstract description 70
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 42
- 201000010099 disease Diseases 0.000 abstract description 20
- 230000001404 mediated effect Effects 0.000 abstract description 7
- 150000001721 carbon Chemical group 0.000 description 43
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- 238000006243 chemical reaction Methods 0.000 description 30
- 238000009472 formulation Methods 0.000 description 30
- 239000007787 solid Substances 0.000 description 27
- 238000002360 preparation method Methods 0.000 description 26
- 239000000243 solution Substances 0.000 description 26
- 239000002904 solvent Substances 0.000 description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 25
- 239000011541 reaction mixture Substances 0.000 description 25
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical class CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 23
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- 208000035475 disorder Diseases 0.000 description 22
- 125000000623 heterocyclic group Chemical group 0.000 description 22
- 150000001412 amines Chemical group 0.000 description 21
- 239000002585 base Chemical class 0.000 description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 19
- 239000002253 acid Substances 0.000 description 18
- LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 description 18
- 239000008186 active pharmaceutical agent Substances 0.000 description 17
- LGEQQWMQCRIYKG-UHFFFAOYSA-N arachidonic acid ethanolamide Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO LGEQQWMQCRIYKG-UHFFFAOYSA-N 0.000 description 17
- 239000002552 dosage form Substances 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 239000003826 tablet Substances 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 239000000843 powder Substances 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 239000010408 film Substances 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 13
- 239000012453 solvate Substances 0.000 description 13
- 206010012289 Dementia Diseases 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 208000019901 Anxiety disease Diseases 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 230000000202 analgesic effect Effects 0.000 description 11
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 208000014674 injury Diseases 0.000 description 10
- 208000004296 neuralgia Diseases 0.000 description 10
- 208000021722 neuropathic pain Diseases 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- 238000006467 substitution reaction Methods 0.000 description 10
- 208000000094 Chronic Pain Diseases 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 8
- 206010046543 Urinary incontinence Diseases 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 208000005298 acute pain Diseases 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 125000004122 cyclic group Chemical group 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000000543 intermediate Substances 0.000 description 8
- 210000000929 nociceptor Anatomy 0.000 description 8
- 108091008700 nociceptors Proteins 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 8
- 229940002612 prodrug Drugs 0.000 description 8
- 239000000651 prodrug Substances 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- ILOIOIGZFHGSMS-UHFFFAOYSA-N 7-phenyl-1-(5-pyridin-2-yl-1,3-oxazol-2-yl)heptan-1-one Chemical compound N=1C=C(C=2N=CC=CC=2)OC=1C(=O)CCCCCCC1=CC=CC=C1 ILOIOIGZFHGSMS-UHFFFAOYSA-N 0.000 description 7
- 208000008035 Back Pain Diseases 0.000 description 7
- 206010065390 Inflammatory pain Diseases 0.000 description 7
- 208000001294 Nociceptive Pain Diseases 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 150000001336 alkenes Chemical class 0.000 description 7
- 125000003118 aryl group Chemical group 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 239000013078 crystal Substances 0.000 description 7
- 125000000753 cycloalkyl group Chemical group 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000011181 potassium carbonates Nutrition 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- 208000009935 visceral pain Diseases 0.000 description 7
- 229910052727 yttrium Inorganic materials 0.000 description 7
- 206010058019 Cancer Pain Diseases 0.000 description 6
- 208000020401 Depressive disease Diseases 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 125000002837 carbocyclic group Chemical group 0.000 description 6
- 208000010877 cognitive disease Diseases 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 150000004677 hydrates Chemical class 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 208000019116 sleep disease Diseases 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 5
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 5
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical class CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 5
- 206010012218 Delirium Diseases 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 108090000371 Esterases Proteins 0.000 description 5
- 206010019233 Headaches Diseases 0.000 description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 5
- 208000016285 Movement disease Diseases 0.000 description 5
- 102000016387 Pancreatic elastase Human genes 0.000 description 5
- 108010067372 Pancreatic elastase Proteins 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 230000036506 anxiety Effects 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 229910052794 bromium Inorganic materials 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000007429 general method Methods 0.000 description 5
- 238000007654 immersion Methods 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- 201000006417 multiple sclerosis Diseases 0.000 description 5
- 150000002825 nitriles Chemical group 0.000 description 5
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 125000004768 (C1-C4) alkylsulfinyl group Chemical group 0.000 description 4
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 4
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 4
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 4
- 125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 description 4
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 4
- 125000004863 4-trifluoromethoxyphenyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C([H])C([H])=C1* 0.000 description 4
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 108091006146 Channels Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 4
- 208000030814 Eating disease Diseases 0.000 description 4
- 208000019454 Feeding and Eating disease Diseases 0.000 description 4
- 208000018522 Gastrointestinal disease Diseases 0.000 description 4
- 208000010412 Glaucoma Diseases 0.000 description 4
- 208000004454 Hyperalgesia Diseases 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 206010020853 Hypertonic bladder Diseases 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 4
- 208000009722 Overactive Urinary Bladder Diseases 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 201000004681 Psoriasis Diseases 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 125000006242 amine protecting group Chemical group 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 208000029028 brain injury Diseases 0.000 description 4
- NBYQXBYMEUOBON-UHFFFAOYSA-N carbamothioyl chloride Chemical compound NC(Cl)=S NBYQXBYMEUOBON-UHFFFAOYSA-N 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 235000014632 disordered eating Nutrition 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 235000019439 ethyl acetate Nutrition 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000003940 fatty acid amidase inhibitor Substances 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 239000003176 neuroleptic agent Substances 0.000 description 4
- 230000000701 neuroleptic effect Effects 0.000 description 4
- 230000001473 noxious effect Effects 0.000 description 4
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 4
- 201000008482 osteoarthritis Diseases 0.000 description 4
- 208000020629 overactive bladder Diseases 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000002085 persistent effect Effects 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 201000000980 schizophrenia Diseases 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 150000003512 tertiary amines Chemical class 0.000 description 4
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 3
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 3
- SUNMBRGCANLOEG-UHFFFAOYSA-N 1,3-dichloroacetone Chemical class ClCC(=O)CCl SUNMBRGCANLOEG-UHFFFAOYSA-N 0.000 description 3
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 3
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 3
- 125000006304 2-iodophenyl group Chemical group [H]C1=C([H])C(I)=C(*)C([H])=C1[H] 0.000 description 3
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 3
- 125000006305 3-iodophenyl group Chemical group [H]C1=C([H])C(I)=C([H])C(*)=C1[H] 0.000 description 3
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 3
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 3
- TXLUTXPEEBIXBF-UHFFFAOYSA-N 5-phenyl-3-(2-piperidin-4-yl-1,3-thiazol-4-yl)-4,5-dihydro-1,2-oxazole Chemical compound C1C(C=2C=CC=CC=2)ON=C1C(N=1)=CSC=1C1CCNCC1 TXLUTXPEEBIXBF-UHFFFAOYSA-N 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- 208000031091 Amnestic disease Diseases 0.000 description 3
- 208000020925 Bipolar disease Diseases 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 208000019022 Mood disease Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 208000004550 Postoperative Pain Diseases 0.000 description 3
- 208000028017 Psychotic disease Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 3
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 3
- 150000001735 carboxylic acids Chemical class 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- KMPWYEUPVWOPIM-LSOMNZGLSA-N cinchonine Chemical compound C1=CC=C2C([C@@H]([C@H]3N4CC[C@H]([C@H](C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-LSOMNZGLSA-N 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 238000006352 cycloaddition reaction Methods 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 229940126534 drug product Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 229960001031 glucose Drugs 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 150000004679 hydroxides Chemical class 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000000155 isotopic effect Effects 0.000 description 3
- 150000002576 ketones Chemical group 0.000 description 3
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 210000004126 nerve fiber Anatomy 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 229960002715 nicotine Drugs 0.000 description 3
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 3
- 230000003040 nociceptive effect Effects 0.000 description 3
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 230000008058 pain sensation Effects 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 208000033808 peripheral neuropathy Diseases 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000002516 radical scavenger Substances 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000001624 sedative effect Effects 0.000 description 3
- 239000011877 solvent mixture Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 235000001508 sulfur Nutrition 0.000 description 3
- 150000003556 thioamides Chemical group 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- WYRSGXAIHNMKOL-UHFFFAOYSA-N $l^{1}-sulfanylethane Chemical compound CC[S] WYRSGXAIHNMKOL-UHFFFAOYSA-N 0.000 description 2
- QSLPNSWXUQHVLP-UHFFFAOYSA-N $l^{1}-sulfanylmethane Chemical compound [S]C QSLPNSWXUQHVLP-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- QXOGPTXQGKQSJT-UHFFFAOYSA-N 1-amino-4-[4-(3,4-dimethylphenyl)sulfanylanilino]-9,10-dioxoanthracene-2-sulfonic acid Chemical compound Cc1ccc(Sc2ccc(Nc3cc(c(N)c4C(=O)c5ccccc5C(=O)c34)S(O)(=O)=O)cc2)cc1C QXOGPTXQGKQSJT-UHFFFAOYSA-N 0.000 description 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- CDVFZPVHQQZOKQ-UHFFFAOYSA-N 2-(2-chlorophenyl)-4-[4-(5-phenyl-4,5-dihydro-1,2-oxazol-3-yl)-1,3-thiazol-2-yl]piperidine-1-carboxylic acid Chemical compound OC(=O)N1CCC(C=2SC=C(N=2)C=2CC(ON=2)C=2C=CC=CC=2)CC1C1=CC=CC=C1Cl CDVFZPVHQQZOKQ-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- IAPUXXZOKAZTNA-UHFFFAOYSA-N 3-chloro-n-hydroxy-2-oxopropanimidoyl chloride Chemical compound ON=C(Cl)C(=O)CCl IAPUXXZOKAZTNA-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 2
- VRODIKIAQUNGJI-UHFFFAOYSA-N 5-phenyl-4,5-dihydro-1,2-oxazole-3-carboxylic acid Chemical compound C1C(C(=O)O)=NOC1C1=CC=CC=C1 VRODIKIAQUNGJI-UHFFFAOYSA-N 0.000 description 2
- 208000008811 Agoraphobia Diseases 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- CKDWPUIZGOQOOM-UHFFFAOYSA-N Carbamyl chloride Chemical compound NC(Cl)=O CKDWPUIZGOQOOM-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- PZKFSRWSQOQYNR-UHFFFAOYSA-N Cc1nnc[nH]1 Chemical compound Cc1nnc[nH]1 PZKFSRWSQOQYNR-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 206010016059 Facial pain Diseases 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- WFJNHVWTKZUUTR-QAMTZSDWSA-N Hydrocinchonine Chemical compound C1=CC=C2C([C@H](O)[C@H]3C[C@@H]4CCN3C[C@@H]4CC)=CC=NC2=C1 WFJNHVWTKZUUTR-QAMTZSDWSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 208000035154 Hyperesthesia Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 208000001738 Nervous System Trauma Diseases 0.000 description 2
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 2
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 208000020114 Schizophrenia and other psychotic disease Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 206010041250 Social phobia Diseases 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 208000010040 Sprains and Strains Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001299 aldehydes Chemical group 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 206010053552 allodynia Diseases 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
- 230000002917 arthritic effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 150000001793 charged compounds Chemical class 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- KMPWYEUPVWOPIM-UHFFFAOYSA-N cinchonidine Natural products C1=CC=C2C(C(C3N4CCC(C(C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 229940127271 compound 49 Drugs 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 description 2
- 125000006310 cycloalkyl amino group Chemical group 0.000 description 2
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 2
- RAFNCPHFRHZCPS-UHFFFAOYSA-N di(imidazol-1-yl)methanethione Chemical compound C1=CN=CN1C(=S)N1C=CN=C1 RAFNCPHFRHZCPS-UHFFFAOYSA-N 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- WFJNHVWTKZUUTR-UHFFFAOYSA-N dihydrocinchonidine Natural products C1=CC=C2C(C(O)C3CC4CCN3CC4CC)=CC=NC2=C1 WFJNHVWTKZUUTR-UHFFFAOYSA-N 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 125000004992 haloalkylamino group Chemical group 0.000 description 2
- 125000004970 halomethyl group Chemical group 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 206010020765 hypersomnia Diseases 0.000 description 2
- 229960004801 imipramine Drugs 0.000 description 2
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- RPCVIAXDAUMJJP-PZBABLGHSA-N ispronicline Chemical compound CN[C@@H](C)C\C=C\C1=CN=CC(OC(C)C)=C1 RPCVIAXDAUMJJP-PZBABLGHSA-N 0.000 description 2
- 238000010902 jet-milling Methods 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 208000024714 major depressive disease Diseases 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000003595 mist Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 230000003232 mucoadhesive effect Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- WWXMPHWMXFPZRQ-UHFFFAOYSA-N n,n-dimethyl-5-phenyl-4,5-dihydro-1,2-oxazole-3-carboxamide Chemical compound C1C(C(=O)N(C)C)=NOC1C1=CC=CC=C1 WWXMPHWMXFPZRQ-UHFFFAOYSA-N 0.000 description 2
- BDGPYQPZSWBEEX-UHFFFAOYSA-N n-(2,5-dimethylphenyl)-4-[4-(5-phenyl-4,5-dihydro-1,2-oxazol-3-yl)-1,3-thiazol-2-yl]piperidine-1-carbothioamide Chemical compound CC1=CC=C(C)C(NC(=S)N2CCC(CC2)C=2SC=C(N=2)C=2CC(ON=2)C=2C=CC=CC=2)=C1 BDGPYQPZSWBEEX-UHFFFAOYSA-N 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 2
- 229940126569 noradrenaline reuptake inhibitor Drugs 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- FATBGEAMYMYZAF-KTKRTIGZSA-N oleamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(N)=O FATBGEAMYMYZAF-KTKRTIGZSA-N 0.000 description 2
- FATBGEAMYMYZAF-UHFFFAOYSA-N oleicacidamide-heptaglycolether Natural products CCCCCCCCC=CCCCCCCCC(N)=O FATBGEAMYMYZAF-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 208000019906 panic disease Diseases 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000012877 positron emission topography Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 150000003254 radicals Chemical group 0.000 description 2
- 239000012429 reaction media Substances 0.000 description 2
- 229960003770 reboxetine Drugs 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- JUOSGGQXEBBCJB-GORDUTHDSA-N rivanicline Chemical compound CNCC\C=C\C1=CC=CN=C1 JUOSGGQXEBBCJB-GORDUTHDSA-N 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 210000003131 sacroiliac joint Anatomy 0.000 description 2
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 239000006068 taste-masking agent Substances 0.000 description 2
- CCKFYPVQHIBLPF-UHFFFAOYSA-N tert-butyl 4-[4-(5-phenyl-4,5-dihydro-1,2-oxazol-3-yl)-1,3-thiazol-2-yl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1=NC(C=2CC(ON=2)C=2C=CC=CC=2)=CS1 CCKFYPVQHIBLPF-UHFFFAOYSA-N 0.000 description 2
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 150000003558 thiocarbamic acid derivatives Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000037816 tissue injury Diseases 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 2
- 210000001170 unmyelinated nerve fiber Anatomy 0.000 description 2
- 235000012431 wafers Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- XMBSMMCPKFDGEO-ZETCQYMHSA-N (2s)-2-amino-5-[[amino-(2-methoxyethylamino)methylidene]amino]pentanoic acid Chemical compound COCCNC(=N)NCCC[C@H](N)C(O)=O XMBSMMCPKFDGEO-ZETCQYMHSA-N 0.000 description 1
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- WRRSFOZOETZUPG-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrate Chemical compound O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC WRRSFOZOETZUPG-FFHNEAJVSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
- MAUMSNABMVEOGP-UHFFFAOYSA-N (methyl-$l^{2}-azanyl)methane Chemical compound C[N]C MAUMSNABMVEOGP-UHFFFAOYSA-N 0.000 description 1
- HXTGXYRHXAGCFP-OAQYLSRUSA-N (r)-(2,3-dimethoxyphenyl)-[1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]methanol Chemical compound COC1=CC=CC([C@H](O)C2CCN(CCC=3C=CC(F)=CC=3)CC2)=C1OC HXTGXYRHXAGCFP-OAQYLSRUSA-N 0.000 description 1
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- COLOHWPRNRVWPI-UHFFFAOYSA-N 1,1,1-trifluoroethane Chemical compound [CH2]C(F)(F)F COLOHWPRNRVWPI-UHFFFAOYSA-N 0.000 description 1
- LQQKDSXCDXHLLF-UHFFFAOYSA-N 1,3-dibromopropan-2-one Chemical class BrCC(=O)CBr LQQKDSXCDXHLLF-UHFFFAOYSA-N 0.000 description 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- JYLLSRXJCBEPFX-UHFFFAOYSA-N 1h-imidazole-2-carbothioamide Chemical class NC(=S)C1=NC=CN1 JYLLSRXJCBEPFX-UHFFFAOYSA-N 0.000 description 1
- YGTUPRIZNBMOFV-UHFFFAOYSA-N 2-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)C1=CC=C(O)C=C1 YGTUPRIZNBMOFV-UHFFFAOYSA-N 0.000 description 1
- XREBYUVOZCUOES-UHFFFAOYSA-N 2-(dimethylamino)-n-hydroxy-2-oxoethanimidoyl chloride Chemical compound CN(C)C(=O)C(Cl)=NO XREBYUVOZCUOES-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- UOPIILYKLVDKTK-UHFFFAOYSA-N 2-[1-(aminomethyl)-3-methylcyclohexyl]acetic acid Chemical compound CC1CCCC(CN)(CC(O)=O)C1 UOPIILYKLVDKTK-UHFFFAOYSA-N 0.000 description 1
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 1
- FQVIRHYXHPBTFZ-UHFFFAOYSA-N 2-chloro-1-(5-phenyl-4,5-dihydro-1,2-oxazol-3-yl)ethanone Chemical compound C1C(C(=O)CCl)=NOC1C1=CC=CC=C1 FQVIRHYXHPBTFZ-UHFFFAOYSA-N 0.000 description 1
- GNXFOGHNGIVQEH-UHFFFAOYSA-N 2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate Chemical compound COC1=CC=CC=C1OCC(O)COC(N)=O GNXFOGHNGIVQEH-UHFFFAOYSA-N 0.000 description 1
- RCBXZRJVMSWGAO-UHFFFAOYSA-N 2-isothiocyanato-1,4-dimethylbenzene Chemical compound CC1=CC=C(C)C(N=C=S)=C1 RCBXZRJVMSWGAO-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- VPIXQGUBUKFLRF-UHFFFAOYSA-N 3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methyl-1-propanamine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCNC)C2=CC=CC=C21 VPIXQGUBUKFLRF-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- WEQPBCSPRXFQQS-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole Chemical compound C1CC=NO1 WEQPBCSPRXFQQS-UHFFFAOYSA-N 0.000 description 1
- FLUWOKHEJWMMEE-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole-3-carboxamide Chemical class NC(=O)C1=NOCC1 FLUWOKHEJWMMEE-UHFFFAOYSA-N 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- YJJYGRGDEYCORZ-UHFFFAOYSA-N 4-carbamothioyl-n-(2,5-dimethylphenyl)piperidine-1-carboxamide Chemical compound CC1=CC=C(C)C(NC(=O)N2CCC(CC2)C(N)=S)=C1 YJJYGRGDEYCORZ-UHFFFAOYSA-N 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229940124125 5 Lipoxygenase inhibitor Drugs 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- BBYLRMNKQBYGNI-UHFFFAOYSA-N 7-amino-3-decanoyl-4-methylchromen-2-one Chemical compound C1=C(N)C=C2OC(=O)C(C(=O)CCCCCCCCC)=C(C)C2=C1 BBYLRMNKQBYGNI-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 102100034452 Alternative prion protein Human genes 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 208000021500 Breathing-related sleep disease Diseases 0.000 description 1
- 208000021465 Brief psychotic disease Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 206010068065 Burning mouth syndrome Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 0 CC*=C(*I)N1CC*(*C2=NOC(*)C2)CC1 Chemical compound CC*=C(*I)N1CC*(*C2=NOC(*)C2)CC1 0.000 description 1
- LWEXEKQKQJELML-UHFFFAOYSA-N CC1=COC=C=N1 Chemical compound CC1=COC=C=N1 LWEXEKQKQJELML-UHFFFAOYSA-N 0.000 description 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor Proteins 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 206010064012 Central pain syndrome Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- 208000006561 Cluster Headache Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 208000023373 Crohn ileitis Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 208000024254 Delusional disease Diseases 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010013980 Dyssomnias Diseases 0.000 description 1
- 239000004097 EU approved flavor enhancer Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- JMBQKKAJIKAWKF-UHFFFAOYSA-N Glutethimide Chemical compound C=1C=CC=CC=1C1(CC)CCC(=O)NC1=O JMBQKKAJIKAWKF-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 208000016588 Idiopathic hypersomnia Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
- JUOSGGQXEBBCJB-UHFFFAOYSA-N Metanicotine Natural products CNCCC=CC1=CC=CN=C1 JUOSGGQXEBBCJB-UHFFFAOYSA-N 0.000 description 1
- JEYCTXHKTXCGPB-UHFFFAOYSA-N Methaqualone Chemical compound CC1=CC=CC=C1N1C(=O)C2=CC=CC=C2N=C1C JEYCTXHKTXCGPB-UHFFFAOYSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000000060 Migraine with aura Diseases 0.000 description 1
- 208000020128 Mitral stenosis Diseases 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 208000023178 Musculoskeletal disease Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229940099433 NMDA receptor antagonist Drugs 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 201000005625 Neuroleptic malignant syndrome Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000000224 Night Terrors Diseases 0.000 description 1
- 206010029412 Nightmare Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
- KYYIDSXMWOZKMP-UHFFFAOYSA-N O-desmethylvenlafaxine Chemical compound C1CCCCC1(O)C(CN(C)C)C1=CC=C(O)C=C1 KYYIDSXMWOZKMP-UHFFFAOYSA-N 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 206010033664 Panic attack Diseases 0.000 description 1
- 206010033668 Panic disorder without agoraphobia Diseases 0.000 description 1
- 208000006199 Parasomnias Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 208000000450 Pelvic Pain Diseases 0.000 description 1
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- 206010056238 Phantom pain Diseases 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010065016 Post-traumatic pain Diseases 0.000 description 1
- 206010073211 Postural tremor Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 201000001177 Pyomyositis Diseases 0.000 description 1
- 208000025535 REM sleep behavior disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 206010038419 Renal colic Diseases 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000277284 Salvelinus fontinalis Species 0.000 description 1
- 208000020186 Schizophreniform disease Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000019568 Shared Paranoid disease Diseases 0.000 description 1
- 208000028810 Shared psychotic disease Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- 208000005439 Sleep paralysis Diseases 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 206010041347 Somnambulism Diseases 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- 206010066218 Stress Urinary Incontinence Diseases 0.000 description 1
- 208000011962 Substance-induced mood disease Diseases 0.000 description 1
- 231100000395 Substance-induced mood disorder Toxicity 0.000 description 1
- 208000011963 Substance-induced psychotic disease Diseases 0.000 description 1
- 231100000393 Substance-induced psychotic disorder Toxicity 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 102000011040 TRPV Cation Channels Human genes 0.000 description 1
- 108010062740 TRPV Cation Channels Proteins 0.000 description 1
- 102000003566 TRPV1 Human genes 0.000 description 1
- 102000003141 Tachykinin Human genes 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
- 208000008548 Tension-Type Headache Diseases 0.000 description 1
- 108010037150 Transient Receptor Potential Channels Proteins 0.000 description 1
- 102000011753 Transient Receptor Potential Channels Human genes 0.000 description 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 101150016206 Trpv1 gene Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000000921 Urge Urinary Incontinence Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 206010047095 Vascular pain Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 208000026345 acute stress disease Diseases 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical group 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001409 amidines Chemical group 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 229960000794 baclofen Drugs 0.000 description 1
- 239000012724 barbiturate sedative Substances 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000004190 benzothiazol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N=C(*)SC2=C1[H] 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 208000022257 bipolar II disease Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 125000005621 boronate group Chemical group 0.000 description 1
- 125000005620 boronic acid group Chemical group 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- DRCMAZOSEIMCHM-UHFFFAOYSA-N capsazepine Chemical compound C1C=2C=C(O)C(O)=CC=2CCCN1C(=S)NCCC1=CC=C(Cl)C=C1 DRCMAZOSEIMCHM-UHFFFAOYSA-N 0.000 description 1
- 229940054025 carbamate anxiolytics Drugs 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 229940077731 carbohydrate nutrients Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- OFZCIYFFPZCNJE-UHFFFAOYSA-N carisoprodol Chemical compound NC(=O)OCC(C)(CCC)COC(=O)NC(C)C OFZCIYFFPZCNJE-UHFFFAOYSA-N 0.000 description 1
- 229960004587 carisoprodol Drugs 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000015111 chews Nutrition 0.000 description 1
- 239000012320 chlorinating reagent Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- AOGYCOYQMAVAFD-UHFFFAOYSA-N chlorocarbonic acid Chemical class OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 description 1
- 125000006425 chlorocyclopropyl group Chemical group 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- TZFWDZFKRBELIQ-UHFFFAOYSA-N chlorzoxazone Chemical compound ClC1=CC=C2OC(O)=NC2=C1 TZFWDZFKRBELIQ-UHFFFAOYSA-N 0.000 description 1
- 229960003633 chlorzoxazone Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- 208000018912 cluster headache syndrome Diseases 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000011280 coal tar Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Natural products C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 238000006880 cross-coupling reaction Methods 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- JURKNVYFZMSNLP-UHFFFAOYSA-N cyclobenzaprine Chemical compound C1=CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 JURKNVYFZMSNLP-UHFFFAOYSA-N 0.000 description 1
- 229960003572 cyclobenzaprine Drugs 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004859 cyclopropyloxymethyl group Chemical group C1(CC1)OC* 0.000 description 1
- 208000026725 cyclothymic disease Diseases 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- SRPXSILJHWNFMK-ZBEGNZNMSA-N desmethylsertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)N)=CC=C(Cl)C(Cl)=C1 SRPXSILJHWNFMK-ZBEGNZNMSA-N 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- ATKXDQOHNICLQW-UHFFFAOYSA-N dichloralphenazone Chemical compound OC(O)C(Cl)(Cl)Cl.OC(O)C(Cl)(Cl)Cl.CN1C(C)=CC(=O)N1C1=CC=CC=C1 ATKXDQOHNICLQW-UHFFFAOYSA-N 0.000 description 1
- 229960005422 dichloralphenazone Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- SPCNPOWOBZQWJK-UHFFFAOYSA-N dimethoxy-(2-propan-2-ylsulfanylethylsulfanyl)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)SCCSC(C)C SPCNPOWOBZQWJK-UHFFFAOYSA-N 0.000 description 1
- FFHWGQQFANVOHV-UHFFFAOYSA-N dimethyldioxirane Chemical compound CC1(C)OO1 FFHWGQQFANVOHV-UHFFFAOYSA-N 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 150000004844 dioxiranes Chemical class 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229960002866 duloxetine Drugs 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 238000007350 electrophilic reaction Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- PWVXXGRKLHYWKM-LJQANCHMSA-N eletriptan Chemical compound CN1CCC[C@@H]1CC(C1=C2)=CNC1=CC=C2CCS(=O)(=O)C1=CC=CC=C1 PWVXXGRKLHYWKM-LJQANCHMSA-N 0.000 description 1
- 229960002472 eletriptan Drugs 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- UXOLDCOJRAMLTQ-UTCJRWHESA-N ethyl (2z)-2-chloro-2-hydroxyiminoacetate Chemical compound CCOC(=O)C(\Cl)=N\O UXOLDCOJRAMLTQ-UTCJRWHESA-N 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 125000006437 ethyl cyclopropyl group Chemical group 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229940044170 formate Drugs 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 244000000004 fungal plant pathogen Species 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229960002972 glutethimide Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000004116 glycogenolysis Effects 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 150000004820 halides Chemical group 0.000 description 1
- 239000000380 hallucinogen Substances 0.000 description 1
- 125000004440 haloalkylsulfinyl group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 229950000177 hibenzate Drugs 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 150000002429 hydrazines Chemical group 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 208000009326 ileitis Diseases 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007916 intrasternal administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007915 intraurethral administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 125000003971 isoxazolinyl group Chemical group 0.000 description 1
- 229950001646 ispronicline Drugs 0.000 description 1
- 229960001848 lamotrigine Drugs 0.000 description 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003913 leukotriene B4 receptor antagonist Substances 0.000 description 1
- 229960004873 levomenthol Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004446 longitudinal ligament Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 240000004308 marijuana Species 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229960004815 meprobamate Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical group CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229960002803 methaqualone Drugs 0.000 description 1
- 229960002330 methocarbamol Drugs 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 229960003404 mexiletine Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 206010052787 migraine without aura Diseases 0.000 description 1
- 229960000600 milnacipran Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 208000006887 mitral valve stenosis Diseases 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 238000003541 multi-stage reaction Methods 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
- PWBJWDKDPAPGED-UHFFFAOYSA-N n'-chlorobutanediamide Chemical compound NC(=O)CCC(=O)NCl PWBJWDKDPAPGED-UHFFFAOYSA-N 0.000 description 1
- VJPYGGPTCRSLFV-UHFFFAOYSA-N n-(2,5-dimethylphenyl)-4-[4-(5-phenyl-4,5-dihydro-1,2-oxazol-3-yl)-1,3-thiazol-2-yl]piperazine-1-carboxamide Chemical compound CC1=CC=C(C)C(NC(=O)N2CCN(CC2)C=2SC=C(N=2)C=2CC(ON=2)C=2C=CC=CC=2)=C1 VJPYGGPTCRSLFV-UHFFFAOYSA-N 0.000 description 1
- MVFXOAIGZVRARG-UHFFFAOYSA-N n-(2,5-dimethylphenyl)formamide Chemical compound CC1=CC=C(C)C(NC=O)=C1 MVFXOAIGZVRARG-UHFFFAOYSA-N 0.000 description 1
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
- QDWUGPSWQZHIER-UHFFFAOYSA-N n-phenyl-4-[4-(5-phenyl-4,5-dihydro-1,2-oxazol-3-yl)-1,3-thiazol-2-yl]piperidine-1-carboxamide Chemical compound C1CC(C=2SC=C(N=2)C=2CC(ON=2)C=2C=CC=CC=2)CCN1C(=O)NC1=CC=CC=C1 QDWUGPSWQZHIER-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005487 naphthalate group Chemical group 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- UNHGSHHVDNGCFN-UHFFFAOYSA-N naratriptan Chemical compound C=12[CH]C(CCS(=O)(=O)NC)=CC=C2N=CC=1C1CCN(C)CC1 UNHGSHHVDNGCFN-UHFFFAOYSA-N 0.000 description 1
- 229960005254 naratriptan Drugs 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000028412 nervous system injury Diseases 0.000 description 1
- 239000002742 neurokinin 1 receptor antagonist Substances 0.000 description 1
- 239000002746 neurokinin 2 receptor antagonist Substances 0.000 description 1
- 239000002740 neurokinin 3 receptor antagonist Substances 0.000 description 1
- 208000037860 neuroleptic-induced Akathisia Diseases 0.000 description 1
- 230000003227 neuromodulating effect Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000002353 niosome Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 238000007034 nitrosation reaction Methods 0.000 description 1
- 208000005346 nocturnal enuresis Diseases 0.000 description 1
- 229960001158 nortriptyline Drugs 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 238000007344 nucleophilic reaction Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229950004864 olamine Drugs 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- BOWVQLFMWHZBEF-KTKRTIGZSA-N oleoyl ethanolamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)NCCO BOWVQLFMWHZBEF-KTKRTIGZSA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 239000000014 opioid analgesic Substances 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 238000010653 organometallic reaction Methods 0.000 description 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 208000024449 overflow incontinence Diseases 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 150000002923 oximes Chemical group 0.000 description 1
- 229960005434 oxybutynin Drugs 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- DVDUMIQZEUTAGK-UHFFFAOYSA-N p-nitrophenyl butyrate Chemical compound CCCC(=O)OC1=CC=C([N+]([O-])=O)C=C1 DVDUMIQZEUTAGK-UHFFFAOYSA-N 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000002851 paranoid schizophrenia Diseases 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N pentanoic acid group Chemical class C(CCCC)(=O)O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229950010883 phencyclidine Drugs 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 1
- DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical class OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- CYQAYERJWZKYML-UHFFFAOYSA-N phosphorus pentasulfide Chemical compound S1P(S2)(=S)SP3(=S)SP1(=S)SP2(=S)S3 CYQAYERJWZKYML-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- QHTPSODXPLCXJB-UHFFFAOYSA-N piperazine;urea Chemical compound NC(N)=O.C1CNCCN1 QHTPSODXPLCXJB-UHFFFAOYSA-N 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 150000004291 polyenes Chemical class 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 1
- 229960001233 pregabalin Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 210000002248 primary sensory neuron Anatomy 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 208000022587 qualitative or quantitative defects of dystrophin Diseases 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- DSDNAKHZNJAGHN-UHFFFAOYSA-N resinferatoxin Natural products C1=C(O)C(OC)=CC(CC(=O)OCC=2CC3(O)C(=O)C(C)=CC3C34C(C)CC5(OC(O4)(CC=4C=CC=CC=4)OC5C3C=2)C(C)=C)=C1 DSDNAKHZNJAGHN-UHFFFAOYSA-N 0.000 description 1
- DSDNAKHZNJAGHN-MXTYGGKSSA-N resiniferatoxin Chemical compound C1=C(O)C(OC)=CC(CC(=O)OCC=2C[C@]3(O)C(=O)C(C)=C[C@H]3[C@@]34[C@H](C)C[C@@]5(O[C@@](O4)(CC=4C=CC=CC=4)O[C@@H]5[C@@H]3C=2)C(C)=C)=C1 DSDNAKHZNJAGHN-MXTYGGKSSA-N 0.000 description 1
- JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 description 1
- 229960003015 rimonabant Drugs 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- TXHZXHICDBAVJW-UHFFFAOYSA-N rizatriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1CN1C=NC=N1 TXHZXHICDBAVJW-UHFFFAOYSA-N 0.000 description 1
- 229960000425 rizatriptan Drugs 0.000 description 1
- 238000009490 roller compaction Methods 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 208000022610 schizoaffective disease Diseases 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000002400 serotonin 2A antagonist Substances 0.000 description 1
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 1
- 239000000952 serotonin receptor agonist Substances 0.000 description 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- 210000004999 sex organ Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940125794 sodium channel blocker Drugs 0.000 description 1
- 239000003195 sodium channel blocking agent Substances 0.000 description 1
- 229960001922 sodium perborate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 201000001716 specific phobia Diseases 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000022170 stress incontinence Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- RYXNTTXRPACDJA-UHFFFAOYSA-N sulfanyl carbonochloridate Chemical compound SOC(Cl)=O RYXNTTXRPACDJA-UHFFFAOYSA-N 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 1
- 229960003708 sumatriptan Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 229940064707 sympathomimetics Drugs 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 108060008037 tachykinin Proteins 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- MKTAGSRKQIGEBH-SSDOTTSWSA-N tebanicline Chemical compound C1=NC(Cl)=CC=C1OC[C@@H]1NCC1 MKTAGSRKQIGEBH-SSDOTTSWSA-N 0.000 description 1
- XLGKMJFDRZHAEV-UHFFFAOYSA-N tert-butyl 4-(4-formyl-1,3-thiazol-2-yl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1=NC(C=O)=CS1 XLGKMJFDRZHAEV-UHFFFAOYSA-N 0.000 description 1
- JBKRAGACGOPWFP-UHFFFAOYSA-N tert-butyl 4-carbamothioylpiperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCN(C(N)=S)CC1 JBKRAGACGOPWFP-UHFFFAOYSA-N 0.000 description 1
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 125000001391 thioamide group Chemical group 0.000 description 1
- ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 description 1
- 150000003585 thioureas Chemical class 0.000 description 1
- 230000009974 thixotropic effect Effects 0.000 description 1
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 description 1
- 229960004045 tolterodine Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 208000018726 traumatic encephalopathy Diseases 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 description 1
- 229940102566 valproate Drugs 0.000 description 1
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 description 1
- 229960004751 varenicline Drugs 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 description 1
- 229960005332 zileuton Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 1
- 229960000607 ziprasidone Drugs 0.000 description 1
- ULSDMUVEXKOYBU-ZDUSSCGKSA-N zolmitriptan Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1C[C@H]1COC(=O)N1 ULSDMUVEXKOYBU-ZDUSSCGKSA-N 0.000 description 1
- 229960001360 zolmitriptan Drugs 0.000 description 1
- 210000002517 zygapophyseal joint Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Definitions
- This invention relates to certain isoxazolyl-substituted piperidine and piperazine urea and carbamate compounds, their N-oxides and the pharmaceutically acceptable salts of such compounds.
- the invention also relates to compositions containing the compounds and the uses of the compounds in treating diseases or conditions associated with fatty acid amide hydrolase activity.
- Fatty acid amides represent a class of signaling lipids with diverse cellular and physiological effects. Fatty acid amides are hydrolyzed to their corresponding fatty acids by an enzyme known as fatty acid amide hydrolase (FAAH).
- FAAH is a mammalian integral membrane serine hydrolase responsible for the hydrolysis of a number of primary and secondary fatty acid amides, including the neuromodulatory compounds anandamide and oleamide.
- Anandamide has been shown to possess cannabinoid-like analgesic properties and is released by stimulated neurons. The effects and endogenous levels of anandamide increase with pain stimulation, implying it has a role in suppressing pain neurotransmission and behavioral analgesia.
- This invention relates to compounds of Formula 1 (including all stereoisomers), N-oxides, and salts thereof:
- A is O, S or NR 6 ;
- W is O or S;
- X is CR 2a or N;
- R 1 is phenyl, naphthalenyl or l,2-benzisoxazol-3-yl, each optionally substituted with up to 3 substituents independently selected from R 5a ; or a 5- to 6-membered heteroaromatic ring, the ring containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, the ring optionally substituted with up to 3 substituents independently selected from R 5a on carbon atom ring members and R 5 ⁇ on nitrogen atom ring members;
- each R 2 is independently halogen, cyano, hydroxy, Ci-C 2 alkyl, Ci ⁇ C 2 haloalkyl or C r C 2 alkoxy;
- R 2a is H, halogen, cyano, hydroxy, i ⁇ C 2 alkyl, Ci ⁇ C 2 haloalkyl or Ci ⁇ C 2 alkoxy; each R 3 is independently halogen, cyano, C1-C3 alkyl or C1-C3 haloalkyl;
- R 4 is C ⁇ -C alkyl, C ⁇ -C haloalkyl, C 3 -C 8 cycloalkyl, C 3 -C 8 halocycloalkyl, C 4 -C 10 alkylcycloalkyl, C 4 -C 10 cycloalkylalkyl, C 2 -C 8 alkoxyalkyl, C 2 -C 8
- haloalkoxyalkyl C4-C10 cycloalkoxyalkyl, C3-C 8 alkoxyalkoxyalkyl, C 2 -Cg alkylthioalkyl, C 2 -Cg alkylsulfinylalkyl, C 2 -Cg alkylsulfonylalkyl, C 2 -Cg alkylaminoalkyl, C 2 -Cg haloalkylaminoalkyl, C3-C 8 dialkylaminoalkyl, C4-C10 cycloalkylaminoalkyl, C j -Cg hydroxyalkyl, C 2 -C 6 alkylcarbonyl, C 2 -C 6 haloalkylcarbonyl, C 2 -Cg alkoxycarbonyl, C 2 -Cg alkylaminocarbonyl or C3-C 8 dialkylaminocarbonyl; or benzyl, phenyl, na
- each R 5a is independently halogen, hydroxy, amino, cyano, nitro, C1-C4 alkyl, C j -Cg haloalkyl, C 3 -C 6 cycloalkyl, C 3 -C 6 halocycloalkyl, C 2 -C 4 alkoxyalkyl, -C4 hydroxyalkyl, -C4 alkoxy, C1-C4 haloalkoxy, -C4 alkylthio, C 1-C4 haloalkylthio, -C4 alkylsulfinyl, C1-C4 alkylsulfonyl, C 1-C4 haloalkylsulfinyl, 1-C4 haloalkylsulfonyl, C 1-C4 alkylamino, C 2 -C 8 dialkylamino, C 2 -C 4 alkylcarbonyl, C 2 -Cg alkoxycarbonyl, C 2 -C
- each R 5b is independently -C4 alkyl, C3-C4 alkenyl, C3-C4 alkynyl, C 3 -C 6
- R 6 is H, C r C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C r C 4 haloalkyl, C 2 -C 4 haloalkenyl, C 2 -C 4 haloalkynyl, C 2 -C 4 alkoxyalkyl, C 2 -C 4 alkylcarbonyl, C 2 -C 4 haloalkylcarbonyl, C ⁇ -C 4 alkylsulfonyl or C ⁇ -C 4 haloalkylsulfonyl;
- G is a 5-membered heteroaromatic ring, the ring containing ring members selected from carbon atoms and 1 to 3 heteroatoms independently selected from up to 2 O, up to 2 S and up to 3 N atoms, the ring optionally substituted with up to 1 substituent selected from R 7a on a carbon atom and R 7b on a nitrogen atom;
- R 7a is halogen, cyano, C ⁇ -C 2 alkyl or C ⁇ -C 2 haloalkyl
- R 7b is C r C 2 alkyl or C r C 2 haloalkyl
- each R 8a is independently halogen, hydroxy, amino, cyano, nitro, C j -C 4 alkyl, C j -C 4 haloalkyl, C j -C 4 alkoxy, C j -C 4 haloalkoxy, C j -C 4 alkylthio, C j -C 4
- haloalkylthio C j -C 4 alkylsulfinyl, C j -C 4 alkylsulfonyl, C j -C 4 haloalkylsulfinyl, C j -Cz j haloalkylsulfonyl, C j -C 4 alkylamino, C 2 -C 6 dialkylamino, C 2 -C 4 alkylcarbonyl, C 2 -Cg alkoxycarbonyl, C 2 -Cg alkylaminocarbonyl or C3 ⁇ Cg dialkylaminocarbonyl; or
- R 8a and R 3 are taken together with the atoms to which they are attached to form a 5- to 7-membered ring, the ring containing ring members selected from carbon atoms and up to 2 heteroatoms independently selected from up to 1 O, up to 1 S and up to 1 N, wherein up to 2 carbon atom ring members are
- each R 8b is independently C ⁇ -C 4 alkyl or C ⁇ -C 4 haloalkyl
- R 8b and R 3 are taken together with the atoms to which they are attached to form a 5- to 7-membered ring, the ring containing ring members selected from carbon atoms and up to 2 heteroatoms independently selected from up to 1 O, up to 1 S and up to 1 N, wherein up to 2 carbon atom ring members are
- each R 9a is independently halogen, C j -C 4 alkyl, C j -C 4 haloalkyl, C j -C 4 alkoxy,
- R 9b is C r C 4 alkyl or C r C 4 haloalkyl
- R 10 is independently H, C j -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C j -C 4 haloalkyl, C 2 -C 4 haloalkenyl, C 2 -C 4 haloalkynyl, C 2 -C 4 alkoxyalkyl, C 2 -C 4 alkylcarbonyl, C 2 -C 4 haloalkylcarbonyl, C j -C 4 alkylsulfonyl or C j -C 4 haloalkylsulfonyl; m is 0, 1 or 2;
- n 0, 1 or 2;
- This invention also relates to pharmaceutical compositions comprising a therapeutically effective amount of a compound of Formula 1, an N-oxide or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier and optionally a further therapeutic agent.
- This invention is also directed to methods of inhibiting fatty acid amide hydrolase activity comprising administering to a subject a compound of Formula 1, an N-oxide or a pharmaceutically acceptable salt thereof to achieve a serum concentration sufficient to inhibit fatty acid amide hydrolase activity in the subject.
- This invention is also directed to methods of treating diseases, disorders or conditions including acute pain, chronic pain, neuropathic pain, nociceptive pain, inflammatory pain, urinary incontinence, overactive bladder, emesis, cognitive disorders, anxiety, depression, sleeping disorders, eating disorders, movement disorders, glaucoma, psoriasis, multiple sclerosis, cerebrovascular disorders, brain injury, gastrointestinal disorders, hypertension, or cardiovascular disease in a subject comprising administering to the subject a therapeutically effective amount of an inhibitor of fatty acid amide hydrolase selected from compounds of Formula 1, N-oxides or pharmaceutically acceptable salts thereof.
- diseases, disorders or conditions including acute pain, chronic pain, neuropathic pain, nociceptive pain, inflammatory pain, urinary incontinence, overactive bladder, emesis, cognitive disorders, anxiety, depression, sleeping disorders, eating disorders, movement disorders, glaucoma, psoriasis, multiple sclerosis, cerebrovascular disorders, brain injury, gastrointestinal disorders, hypertension, or cardiovascular disease in
- This invention is also directed to pharmaceutical compositions comprising a therapeutically effective amount of a compound of Formula 1, an N-oxide or a pharmaceutically acceptable salt thereof for use in treating FAAH-mediated diseases, disorders or conditions including acute pain, chronic pain, neuropathic pain, nociceptive pain, inflammatory pain, urinary incontinence, overactive bladder, emesis, cognitive disorders, anxiety, depression, sleeping disorders, eating disorders, movement disorders, glaucoma, psoriasis, multiple sclerosis, cerebrovascular disorders, brain injury, gastrointestinal disorders, hypertension, or cardiovascular disease.
- FAAH-mediated diseases, disorders or conditions including acute pain, chronic pain, neuropathic pain, nociceptive pain, inflammatory pain, urinary incontinence, overactive bladder, emesis, cognitive disorders, anxiety, depression, sleeping disorders, eating disorders, movement disorders, glaucoma, psoriasis, multiple sclerosis, cerebrovascular disorders, brain injury, gastrointestinal disorders, hypertension, or cardiovascular disease.
- This invention is also directed to pharmaceutical compositions comprising a therapeutically effective amount of a compound of Formula 1, an N-oxide or a pharmaceutically acceptable salt thereof for use in the manufacture of a medicament for the treatment of FAAH-mediated diseases, disorders or conditions including acute pain, chronic pain, neuropathic pain, nociceptive pain, inflammatory pain, urinary incontinence, overactive bladder, emesis, cognitive disorders, anxiety, depression, sleeping disorders, eating disorders, movement disorders, glaucoma, psoriasis, multiple sclerosis, cerebrovascular disorders, brain injury, gastrointestinal disorders, hypertension, or cardiovascular disease.
- This invention relates to compounds of Formula 1 and pharmaceutically acceptable salts which are effective for inhibiting the activity of FAAH.
- Inhibition of FAAH activity can be measured by any method known in the art, for example, by measuring elevation in levels of fatty acid amides such as anandamide, oleamide, N-palmitoyl ehanolamide, and N-oleoyl ethanolamide.
- the invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of a compound of Formula 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
- This invention is also directed to methods of treating FAAH-mediated diseases, disorders or conditions including acute pain, chronic pain, neuropathic pain, nociceptive pain, inflammatory pain, urinary incontinence, overactive bladder, emesis, cognitive disorders, anxiety, depression, sleeping disorders, eating disorders, movement disorders, glaucoma, psoriasis, multiple sclerosis, cerebrovascular disorders, brain injury, gastrointestinal disorders, hypertension, or cardiovascular disease in a subject by administering to a subject a therapeutically effective amount of one or more of the compounds of Formula 1 or a pharmaceutically acceptable salt thereof.
- the term "subject” refers to a mammal, including humans.
- the term “treating” refers to reversing, alleviating, inhibiting the progress of, or preventing a disease, disorder or condition to which such term applies, or to reversing, alleviating, inhibiting the progress of, or preventing one or more symptoms of such disease, disorder or condition.
- the phrase "therapeutically effective amount” refers to the quantity of a compound that may be used for treating a subject, which amount may depend on the weight and age of the subject and the route of administration, among other things.
- excipient or “adjuvant” refer to any substance in a pharmaceutical formulation that is not an active pharmaceutical ingredient (API).
- pharmaceutical composition refers to the combination of one or more drug substances and one or more excipients.
- drug product refers to a pharmaceutical composition that is administered to a subject in need of treatment and generally may be in the form of tablets, capsules, liquid solutions or suspensions, patches, films and the like.
- Physiological pain is an important protective mechanism designed to warn of danger from potentially injurious stimuli from the external environment.
- the system operates through a specific set of primary sensory neurons and is activated by noxious stimuli via peripheral transducing mechanisms (see Millan, Prog. Neurobiol. 1999, 57, 1-164 for a review).
- These sensory fibers are known as nociceptors and are characteristically small diameter axons with slow conduction velocities. Nociceptors encode the intensity, duration and quality of noxious stimulus and by virtue of their topographically organized projection to the spinal cord, the location of the stimulus.
- the nociceptors are found on nociceptive nerve fibers of which there are two main types, A-delta fibers (myelinated) and C fibers (non-myelinated).
- A-delta fibers myelinated
- C fibers non-myelinated.
- the activity generated by nociceptor input is transferred, after complex processing in the dorsal horn, either directly, or via brain stem relay nuclei, to the ventrobasal thalamus and then on to the cortex, where the sensation of pain is generated.
- Pain may generally be classified as acute or chronic. Acute pain begins suddenly and is short-lived (usually twelve weeks or less). It is usually associated with a specific cause such as a specific injury and is often sharp and severe. It is the kind of pain that can occur after specific injuries resulting from surgery, dental work, a strain or a sprain. Acute pain does not generally result in any persistent psychological response. In contrast, chronic pain is long-term pain, typically persisting for more than three months and leading to significant psychological and emotional problems. Common examples of chronic pain are neuropathic pain (e.g., painful diabetic neuropathy, postherpetic neuralgia), carpal tunnel syndrome, back pain, headache, cancer pain, arthritic pain and chronic post-surgical pain.
- neuropathic pain e.g., painful diabetic neuropathy, postherpetic neuralgia
- carpal tunnel syndrome e.g., painful diabetic neuropathy, postherpetic neuralgia
- back pain e.g., painful diabetic neuropathy, postherpetic neuralg
- Clinical pain is present when discomfort and abnormal sensitivity feature among the patient's symptoms. Patients tend to be quite heterogeneous and may present with various pain symptoms. Such symptoms include: (1) spontaneous pain which may be dull, burning, or stabbing; (2) exaggerated pain responses to noxious stimuli (hyperalgesia); and (3) pain produced by normally innocuous stimuli (allodynia - Textbook of Pain Meyer et al. 1994, 13- 44). Although patients suffering from various forms of acute and chronic pain may have similar symptoms, the underlying mechanisms may be different and may, therefore, require different treatment strategies. Pain can also therefore be divided into a number of different subtypes according to differing pathophysiology, including nociceptive, inflammatory and neuropathic pain.
- Nociceptive pain is induced by tissue injury or by intense stimuli with the potential to cause injury. Pain afferents are activated by transduction of stimuli by nociceptors at the site of injury and activate neurons in the spinal cord at the level of their termination. This is then relayed up the spinal tracts to the brain where pain is perceived (Textbook of Pain, Meyer et al, 1994, 13-44). The activation of nociceptors activates two types of afferent nerve fibers. Myelinated A-delta fibers transmit rapidly and are responsible for sharp and stabbing pain sensations, while unmyelinated C fibers transmit at a slower rate and convey a dull or aching pain.
- Moderate to severe acute nociceptive pain is a prominent feature of pain from central nervous system trauma, strains/sprains, burns, myocardial infarction and acute pancreatitis, postoperative pain (pain following any type of surgical procedure), posttraumatic pain, renal colic, cancer pain and back pain.
- Cancer pain may be chronic pain such as tumor related pain (e.g., bone pain, headache, facial pain or visceral pain) or pain associated with cancer therapy (e.g., postchemotherapy syndrome, chronic postsurgical pain syndrome or post radiation syndrome). Cancer pain may also occur in response to chemotherapy, immunotherapy, hormonal therapy or radiotherapy.
- Back pain may be due to herniated or ruptured intervertabral discs or abnormalities of the lumber facet joints, sacroiliac joints, paraspinal muscles or the posterior longitudinal ligament. Back pain may resolve naturally but in some patients, where it lasts over 12 weeks, it becomes a chronic condition which can be particularly debilitating.
- Neuropathic pain is currently defined as pain initiated or caused by a primary lesion or dysfunction in the nervous system. Nerve damage can be caused by trauma and disease and thus the term "neuropathic pain” encompasses many disorders with diverse etiologies. These include, but are not limited to, peripheral neuropathy, diabetic neuropathy, post herpetic neuralgia, trigeminal neuralgia, back pain, cancer neuropathy, HIV neuropathy, phantom limb pain, carpal tunnel syndrome, central post-stroke pain and pain associated with chronic alcoholism, hypothyroidism, uremia, multiple sclerosis, spinal cord injury, Parkinson's disease, epilepsy and vitamin deficiency. Neuropathic pain is pathological as it has no protective role.
- neuropathic pain are difficult to treat, as they are often heterogeneous even between patients with the same disease (Woolf & Decosterd Pain Supp. 1999, 6, S141-S147; Woolf and Mannion Lancet 1999, 353, 1959- 1964). They include spontaneous pain, which can be continuous, and paroxysmal or abnormal evoked pain, such as hyperalgesia (increased sensitivity to a noxious stimulus) and allodynia (sensitivity to a normally innocuous stimulus).
- the inflammatory process is a complex series of biochemical and cellular events, activated in response to tissue injury or the presence of foreign substances, which results in swelling and pain ⁇ Textbook of Pain Levine and Taiwo, 1994, 45-56).
- Arthritic pain is the most common inflammatory pain.
- Rheumatoid disease is one of the commonest chronic inflammatory conditions in developed countries and rheumatoid arthritis is a common cause of disability.
- the exact etiology of rheumatoid arthritis is unknown, but current hypotheses suggest that both genetic and microbiological factors may be important ⁇ Textbook of Pain Grennan & Jayson, 1994, 397-407).
- Visceral pain is pain associated with the viscera, which encompass the organs of the abdominal cavity. These organs include the sex organs, spleen and part of the digestive system. Pain associated with the viscera can be divided into digestive visceral pain and non-digestive visceral pain.
- GI gastrointestinal
- BBD functional bowel disorder
- IBD inflammatory bowel disease
- GI disorders include a wide range of disease states that are currently only moderately controlled, including, in respect of FBD, gastroesophageal reflux, dyspepsia, irritable bowel syndrome (IBS) and functional abdominal pain syndrome (FAPS), and, in respect of IBD, Crohn's disease, ileitis and ulcerative colitis, all of which regularly produce visceral pain.
- Other types of visceral pain include the pain associated with dysmenorrhea, cystitis and pancreatitis and pelvic pain.
- pain have multiple etiologies and thus can be classified in more than one area, e.g., back pain and cancer pain have both nociceptive and neuropathic components.
- Other types of pain include pain resulting from musculo-skeletal disorders, including myalgia, fibromyalgia, spondylitis, sero-negative (non-rheumatoid) arthropathies, non-articular rheumatism, dystrophinopathy, glycogenolysis, polymyositis and pyomyositis; heart and vascular pain, including pain caused by angina, myocardical infarction, mitral stenosis, pericarditis, Raynaud's phenomenon, scleredoma and skeletal muscle ischemia; head pain, such as migraine (including migraine with aura and migraine without aura), cluster headache, tension-type headache mixed headache and headache associated with vascular disorders; and orofacial pain, including dental pain, otic pain, burning
- the compounds herein, and the pharmaceutically acceptable salts thereof can be used to treat CNS disorders, including schizophrenia and other psychotic disorders, mood disorders, anxiety disorders, sleep disorders, and cognitive disorders, such as delirium, dementia, and amnestic disorders.
- CNS disorders including schizophrenia and other psychotic disorders, mood disorders, anxiety disorders, sleep disorders, and cognitive disorders, such as delirium, dementia, and amnestic disorders.
- the standards for diagnosis of these disorders can be found in the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders (4th ed., 2000), which is commonly referred to as the DSM Manual.
- schizophrenia and other psychotic disorders include schizophreniform disorder, schizoaffective disorder, delusional disorder, brief psychotic disorder, shared psychotic disorder, psychotic disorder due to general medical condition, and substance-induced psychotic disorder, as well as medication-induced movement disorders, such as neuroleptic-induced Parkinsonism, neuroleptic malignant syndrome, neuroleptic-induced acute dystonia, neuroleptic-induced acute akathisia, neuroleptic-induced tardive dyskinesia, and medication-induced postural tremor.
- medication-induced movement disorders such as neuroleptic-induced Parkinsonism, neuroleptic malignant syndrome, neuroleptic-induced acute dystonia, neuroleptic-induced acute akathisia, neuroleptic-induced tardive dyskinesia, and medication-induced postural tremor.
- Mood disorders include depressive disorders, such as major depressive disorder, dysthymic disorder, premenstrual dysphoric disorder, minor depressive disorder, recurrent brief depressive disorder, postpsychotic depressive disorder of schizophrenia, and major depressive episode with schizophrenia; bipolar disorders, such as bipolar I disorder, bipolar II disorder, cyclothymia, and bipolar disorder with schizophrenia; mood disorders due to general medical condition; and substance-induced mood disorders.
- Anxiety disorders include panic attack, agoraphobia, panic disorder without agoraphobia, agoraphobia without history of panic disorder, specific phobia, social phobia (social anxiety disorder), obsessive-compulsive disorder, posttraumatic stress disorder, acute stress disorder, generalized anxiety disorder, anxiety disorder due to general medical condition, substance-induced anxiety disorder, and mixed anxiety-depressive disorder.
- Sleep disorders include primary sleep disorders, such as dyssomnias (primary insomnia, primary hypersomnia, narcolepsy, breathing-related sleep disorder, circadian rhythm sleep disorder, sleep deprivation, restless legs syndrome, and periodic limb movements) and parasomnias (nightmare disorder, sleep terror disorder, sleepwalking disorder, rapid eye movement sleep behavior disorder, and sleep paralysis); sleep disorders related to another mental disorder, including insomnia related to schizophrenia, depressive disorders, or anxiety disorders, or hypersomnia associated with bipolar disorders; sleep disorders due to a general medical condition; and substance-induced sleep disorders.
- dyssomnias primary insomnia, primary hypersomnia, narcolepsy, breathing-related sleep disorder, circadian rhythm sleep disorder, sleep deprivation, restless legs syndrome, and periodic limb movements
- parasomnias nightmare disorder, sleep terror disorder, sleepwalking disorder, rapid eye movement sleep behavior disorder, and sleep paralysis
- sleep disorders related to another mental disorder including insomnia related to schizophrenia, depressive disorders, or anxiety disorders, or hypersomni
- Delirium, dementia, and amnestic and other cognitive disorders includes delirium due to a general medical condition, substance-induced delirium, and delirium due to multiple etiologies; dementia of the Alzheimer's type, vascular dementia, dementia due to general medical conditions, dementia due to human immunodeficiency virus disease, dementia due to head trauma, dementia due to Parkinson's disease, dementia due to Huntington's disease, dementia due to Pick's disease, dementia due to Creutzfeldt- Jakob disease, dementia due to other general medical conditions, substance-induced persisting dementia, dementia due to multiple etiologies; amnestic disorders due to a general medical condition, and substance- induced persisting amnestic disorder.
- Substance-induced disorders refer to those resulting from the using, abusing, dependence on, or withdrawal from, one or more drugs or toxins, including alcohol, amphetamines or similarly acting sympathomimetics, caffeine, cannabis, cocaine, hallucinogens, inhalants, nicotine, opioids, phencyclidine or similarly acting arylcyclohexylamines, and sedatives, hypnotics, or anxiolytics, among others.
- drugs or toxins including alcohol, amphetamines or similarly acting sympathomimetics, caffeine, cannabis, cocaine, hallucinogens, inhalants, nicotine, opioids, phencyclidine or similarly acting arylcyclohexylamines, and sedatives, hypnotics, or anxiolytics, among others.
- Urinary incontinence includes the involuntary or accidental loss of urine due to the inability to restrain or control urinary voiding. Urinary incontinence includes mixed urinary incontinence, nocturnal enuresis, overflow incontinence, stress incontinence, transient urinary incontinence, and urge incontinence.
- compositions comprising, “comprising,” “includes,” “including,” “has,” “having,” “contains”, “containing,” “characterized by” or any other variation thereof, are intended to cover a non-exclusive inclusion, subject to any limitation explicitly indicated.
- a composition, mixture, process or method that comprises a list of elements is not necessarily limited to only those elements but may include other elements not expressly listed or inherent to such composition, mixture, process or method.
- transitional phrase consisting essentially of is used to define a composition or method that includes materials, steps, features, components, or elements, in addition to those literally disclosed, provided that these additional materials, steps, features, components, or elements do not materially affect the basic and novel characteristic(s) of the claimed invention.
- alkyl used either alone or in compound words such as “alkylthio” or “haloalkyl” includes straight-chain or branched alkyl, such as, methyl, ethyl, n-propyl, /-propyl, and the different butyl isomers.
- alkenyl includes straight-chain or branched alkenes such as ethenyl, 1-propenyl, 2-propenyl, and the different butenyl isomers.
- Alkenyl also includes polyenes such as 1 ,2-propadienyl.
- Alkynyl includes straight-chain or branched alkynes such as ethynyl, 1-propynyl, 2-propynyl, and the different butynyl isomers.
- Alkoxy includes, for example, methoxy, ethoxy, n-propyloxy, /-propyloxy, and the different butoxy isomers.
- Alkylthio includes branched or straight-chain alkylthio moieties such as methylthio, ethylthio, and the different propylthio and butylthio isomers.
- Alkylsulfmyl includes both enantiomers of an alkylsulfmyl group.
- Alkylamino includes an NH radical substituted with straight-chain or branched alkyl.
- alkylamino examples include CH 3 CH 2 NH, CH 3 CH 2 CH 2 NH and (CH 3 ) 2 CHCH 2 NH.
- dialkylamino examples include (CH 3 ) 2 N, (CH 3 CH 2 CH 2 ) 2 N and CH 3 CH 2 (CH 3 )N.
- Alkoxyalkyl denotes alkoxy substitution on alkyl.
- alkoxyalkyl examples include CH 3 OCH 2 , CH 3 OCH 2 CH 2 , CH 3 CH 2 OCH 2 , CH 3 CH 2 CH 2 CH 2 OCH 2 and CH 3 CH 2 OCH 2 CH 2 .
- alkylcarbonyloxy denotes straight-chain or branched alkylcarbonyl attached to and linked through an oxygen atom.
- Alkoxyalkoxyalkyl denotes alkoxy substitution on alkoxyalkyl.
- alkoxyalkoxyalkyl include CH 3 OCH 2 OCH 2 , CH 3 OCH 2 OCH 2 CH 2 , CH 3 CH 2 OCH 2 OCH 2 and CH 3 OCH 3 CH 2 OCH 2 CH 2 .
- Alkylthioalkyl denotes alkylthio substitution on alkyl.
- alkylthioalkyl include CH 3 SCH 2 , CH 3 SCH 2 CH 2 , CH 3 CH 2 SCH 2 , CH 3 CH 2 CH 2 CH 2 SCH 2 and CH 3 CH 2 SCH 2 CH 2 ;
- alkylsulfmylalkyl and “alkylsulfonylalkyl” include the corresponding sulfoxides and sulfones, respectively.
- Alkylaminoalkyl denotes alkylamino substitution on alkyl.
- alkylaminoalkyl include CH 3 NHCH 2 , CH 3 NHCH 2 CH 2 , CH 3 CH 2 NHCH 2 , CH 3 CH 2 CH 2 CH 2 NHCH 2 and CH 3 CH 2 NHCH 2 CH 2 .
- dialkylaminoalkyl include ((CH 3 ) 2 CH) 2 NCH 2 , (CH 3 CH 2 CH 2 ) 2 NCH 2 and CH 3 CH 2 (CH 3 )NCH 2 CH 2 .
- Hydroxyalkyl denotes an alkyl group substituted with one hydroxy group.
- Examples of “hydroxyalkyl” include HOCH 2 CH 2 , CH 3 CH 2 (OH)CH and HOCH 2 CH 2 CH 2 CH 2 .
- cycloalkyl denotes a saturated carbocyclic ring consisting of 3 to 8 carbon atoms linked to one another by single bonds.
- Examples of “cycloalkyl” include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
- alkylcycloalkyl denotes alkyl substitution on a cycloalkyl moiety and includes, for example, ethylcyclopropyl, z-propylcyclobutyl, methylcyclopentyl and methylcyclohexyl.
- cycloalkylalkyl denotes cycloalkyl substitution on an alkyl moiety.
- cycloalkylalkyl examples include cyclopropylmethyl, cyclopentylethyl, and other cycloalkyl moieties bonded to straight-chain or branched alkyl groups.
- cycloalkoxyalkyl denotes cycloalkoxy substitution on an alkyl moiety.
- examples of “cycloalkoxyalkyl” include cyclopropyloxymethyl, cyclopentyloxyethyl, and other cycloalkoxy moieties bonded to straight-chain or branched alkyl groups.
- cycloalkylaminoalkyl denotes cycloalkylamino substitution on an alkyl group.
- cycloalkylaminoalkyl examples include cyclopropylaminomethyl, cyclopentylaminoethyl, and other cycloalkylamino moieties bonded to straight-chain or branched alkyl groups.
- Trialkylsilyl includes 3 branched and/or straight-chain alkyl radicals attached to and linked through a silicon atom, such as trimethylsilyl, triethylsilyl and tert-butyldimethylsilyl.
- halogen either alone or in compound words such as “haloalkyl”, or when used in descriptions such as “alkyl substituted with halogen” includes fluorine, chlorine, bromine or iodine. Further, when used in compound words such as “haloalkyl”, or when used in descriptions such as “alkyl substituted with halogen” said alkyl may be partially or fully substituted with halogen atoms which may be the same or different. Examples of “haloalkyl” or “alkyl substituted with halogen” include F 3 C, C1CH 2 , CF 3 CH 2 and CF 3 CC1 2 .
- haloalkynyl examples include HC ⁇ CCHC1, CF 3 C ⁇ C, CC1 3 C ⁇ C and FCH 2 C ⁇ CCH 2 .
- haloalkoxy examples include CF 3 0, CC1 3 CH 2 0, F 2 CHCH 2 CH 2 0 and CF 3 CH 2 0.
- haloalkylthio examples include CC1 3 S, CF 3 S, CC1 3 CH 2 S and C1CH 2 CH 2 CH 2 S.
- halocycloalkyl examples include chlorocyclopropyl, fluorocyclobutyl and chlorocyclohexyl.
- C j -Cj The total number of carbon atoms in a substituent group is indicated by the "C j -Cj" prefix where i and j are numbers from 1 to 10.
- C 1 -C4 alkylsulfonyl designates methylsulfonyl through butylsulfonyl
- C 2 alkoxyalkyl designates CH 3 OCH 2
- C 3 alkoxyalkyl designates, for example, CH 3 OCH 2 CH 2 or CH 3 CH 2 OCH 2
- C 4 alkoxyalkyl designates the various isomers of an alkyl group substituted with an alkoxy group containing a total of four carbon atoms, examples including CH 3 CH 2 CH 2 OCH 2 and CH 3 CH 2 OCH 2 CH 2 .
- the number of optional substituents may be restricted by an expressed limitation.
- the phrase “optionally substituted with up to 2 substituents independently selected from R 9a on carbon atom ring members” means that 0, 1 or 2 substituents can be present (if the number of potential connection points allows).
- the phrase “optionally substituted with up to 3 substituents independently selected from R 5a on carbon atom ring members” means that 0, 1, 2 or 3 substituents can be present if the number of available connection points allows.
- said substituents When a group is substituted with a substituent bearing a subscript that indicates the number of said substituents can exceed 1, said substituents (when they exceed 1) are independently selected from the group of defined substituents (e.g., (R v )k wherein k is 1, 2, or 3 in Exhibit 1).
- substituents When a group is substituted with a substituent bearing a subscript that indicates the substituent to be optionally attached, for example (R 3 ) m wherein m can be zero, then hydrogen may be at the position regardless of wherther hydrogen is recited in the variable group definition.
- Aromatic indicates that each of the ring atoms is essentially in the same plane and has a / ⁇ -orbital perpendicular to the ring plane, and that (4n + 2) ⁇ electrons, where n is a positive integer, are associated with the ring to comply with Huckel's rule.
- An aromatic ring system denotes a carbocyclic or heterocyclic ring system in which at least one ring of the ring system is aromatic.
- An aromatic heterocyclic ring system denotes a heterocyclic ring system in which at least one ring of the ring system is aromatic.
- carbocyclic ring denotes a ring wherein the atoms forming the ring backbone are selected only from carbon. Unless otherwise indicated, a carbocyclic ring can be a saturated, partially unsaturated, or fully unsaturated ring. When a fully unsaturated carbocyclic ring satisfies Huckel's rule, then said ring is also called an "aromatic ring". "Saturated carbocyclic” refers to a ring having a backbone consisting of carbon atoms linked to one another by single bonds; unless otherwise specified, the remaining carbon valences are occupied by hydrogen atoms.
- heterocyclic ring denotes a ring or ring system in which at least one atom forming the ring backbone is not carbon, e.g., nitrogen, oxygen or sulfur.
- a heterocyclic ring contains no more than 2 nitrogens, no more than 2 oxygens and no more than 2 sulfurs.
- a heterocyclic ring can be a saturated, partially unsaturated, or fully unsaturated ring. When a fully unsaturated heterocyclic ring satisfies Huckel's rule, then said ring is also called a “heteroaromatic ring” or “aromatic heterocyclic ring”.
- heterocyclic rings and ring systems can be attached through any available carbon or nitrogen by replacement of a hydrogen on said carbon or nitrogen.
- R 8a and R 3 substituents may also be connected to form a ring.
- the portion of the ring form by joining R 8a and R 3 can contain 5-, 6- or 7-members including as ring members the two carbon atoms to which the substituents R 8a and R 3 are attached.
- the other 3 to 5 ring members are provided by the pair of R 8a and R 3 substituents taken together.
- the heteroatoms are optional, because the number of heteroatom ring members may be zero.
- the nitrogen atom ring members may be oxidized as N-oxides, because compounds relating to Formula 1 also include N-oxide derivatives.
- the portion of the ring system formed by the pair of R 8a and R 3 taken together can be optionally substituted with up to 2 substituents independently selected from R 9a on carbon atom ring members and R 9 ⁇ on the nitrogen atom ring member.
- a pair of R 8 ⁇ and R 3 substituents may also be connected to form a ring.
- the portion of the ring taken form by joining R 8 ⁇ and R 3 can contain 5-, 6- or 7-members including as ring members the carbon and nitrogen atoms to which the substituents R 8 ⁇ and R 3 are attached.
- the other 3 to 5 ring members are provided by the pair of R 8 ⁇ and R 3 substituents taken together.
- the nitrogen atom ring members may be oxidized as N-oxides, because compounds relating to Formula 1 also include N-oxide derivatives.
- the portion of the ring system formed by the pair of R 8 ⁇ and R 3 taken together can be optionally substituted with up to 2 substituents independently selected from R 9a on carbon atom ring members and R 9 ⁇ on the nitrogen atom ring member.
- Compounds of this invention can exist as one or more stereoisomers.
- the various stereoisomers include enantiomers, diastereomers, atropisomers and geometric isomers.
- one stereoisomer may be more active and/or may exhibit beneficial effects when enriched relative to the other stereoisomer(s) or when separated from the other stereoisomer(s). Additionally, the skilled artisan knows how to separate, enrich, and/or to selectively prepare said stereoisomers.
- the compounds of the invention may be present as a mixture of stereoisomers, individual stereoisomers or as an optically active form.
- Formula 1 possesses a chiral center at the carbon atom to which R 4 is bonded.
- the two enantiomers are depicted as Formula 1' and Formula 1" with the chiral center identified with an asterisk *).
- Compounds of Formula 1 comprise racemic mixtures, for example, equal amounts of the enantiomers of Formulae 1' and 1".
- compounds of Formula 1 include compounds that are enriched compared to the racemic mixture in an enantiomer of Formula 1. Also included are the essentially pure enantiomers of compounds of Formula 1, for example, Formula 1' and Formula 1".
- Compounds of Formula 1 can comprise additional chiral centers.
- substituents and other molecular constituents such as R 2 and R 3 may themselves contain chiral centers.
- This invention comprises racemic mixtures as well as enriched and essentially pure stereoconfigurations at these additional chiral centers.
- enantiomeric excess which is defined as (2 ⁇ -1) ⁇ 100%, where x is the mole fraction of the dominant enantiomer in the mixture (e.g., an ee of 20% corresponds to a 60:40 ratio of enantiomers).
- compositions of this invention of Formula 1 have at least a 50% enantiomeric excess; more preferably at least a 75% enantiomeric excess; still more preferably at least a 90% enantiomeric excess; and the most preferably at least a 94% enantiomeric excess of the more active isomer.
- enantiomerically pure embodiments of the more active isomer are enantiomerically pure embodiments of the more active isomer.
- Compounds of Formula 1 comprise mixtures of conformational isomers.
- compounds of Formula 1 include compounds that are enriched in one conformer relative to others.
- the compounds of the present invention include N-oxide derivatives of Formula 1.
- nitrogen-containing heterocycles can form N-oxides since the nitrogen requires an available lone pair of electrons for oxidation to the oxide; one skilled in the art will recognize those nitrogen-containing heterocycles which can form N-oxides.
- tertiary amines can form N-oxides.
- N-oxides of heterocycles and tertiary amines are very well known by one skilled in the art including the oxidation of heterocycles and tertiary amines with peroxy acids such as peracetic and m-chloroperbenzoic acid (MCPBA), hydrogen peroxide, alkyl hydroperoxides such as tert-butyl hydroperoxide, sodium perborate, and dioxiranes such as dimethyldioxirane.
- MCPBA peroxy acids
- alkyl hydroperoxides such as tert-butyl hydroperoxide
- sodium perborate sodium perborate
- dioxiranes such as dimethyldioxirane
- salts of chemical compounds are in equilibrium with their corresponding nonsalt forms, salts share the biological utility of the nonsalt forms.
- the compounds forming the present mixtures and compositions contain acidic or basic moieties, a wide variety of salts can be formed, and these salts are useful in the present mixtures and compositions for controlling plant diseases caused by fungal plant pathogens (i.e. are agriculturally suitable).
- salts include acid-addition salts with inorganic or organic acids such as hydrobromic, hydrochloric, nitric, phosphoric, sulfuric, acetic, butyric, fumaric, lactic, maleic, malonic, oxalic, propionic, salicylic, tartaric, 4-toluenesulfonic or valeric acids.
- inorganic or organic acids such as hydrobromic, hydrochloric, nitric, phosphoric, sulfuric, acetic, butyric, fumaric, lactic, maleic, malonic, oxalic, propionic, salicylic, tartaric, 4-toluenesulfonic or valeric acids.
- salts include those formed with organic or inorganic bases such as pyridine, triethylamine or ammonia, or amides, hydrides, hydroxides or carbonates of sodium, potassium, lithium, calcium, magnesium or barium.
- the compounds described and specifically named herein may form pharmaceutically acceptable complexes, salts, solvates and hydrates.
- the salts include acid addition salts and base salts.
- Pharmaceutically acceptable acid addition salts include salts derived from inorganic acids such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, hydrofluoric acid, and phosphorous acids, as well salts derived from organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc.
- Such salts include acetate, adipate, aspartate, benzoate, besylate, bicarbonate, carbonate, bisulfate, sulfate, borate, camsylate, citrate, cyclamate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochloride, chloride, hydrobromide, bromide, hydroiodide, iodide, isothionate, lactate, malate, maleate, malonate, mesylate, methylsulfate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, almitate, pamoate, phosphate, hydrogen phosphate, dihydrogen phosphate, pyroglutamate, saccharate, stearate, succinate, tannate, tartrate
- Pharmaceutically acceptable base salts include salts derived from bases, including metal cations, such as an alkali or alkaline earth metal cation, as well as amines.
- suitable metal cations include sodium (Na + ), potassium (K + ), magnesium (Mg 2+ ), calcium (Ca 2+ ), zinc (Zn 2+ ), and aluminum (Al 3+ ).
- Suitable amines include arginine, ⁇ , ⁇ '-dibenzylethylenediamine, chloroprocaine, choline, diethylamine, diethanolamine, dicyclohexylamine, ethylenediamine, glycine, lysine, N-methylglucamine, olamine, 2-amino-2-hydroxymethyl-propane-l,3-diol, and procaine.
- solvate describes a molecular complex comprising the compound and one or more pharmaceutically acceptable solvent molecules (e.g., EtOH).
- solvent molecules e.g., EtOH
- hydrate is a solvate in which the solvent is water.
- Pharmaceutically acceptable solvates include those in which the solvent may be isotopically substituted (e.g., D 2 0, d 6 -acetone, d 6 -DMSO).
- Isolated site solvates and hydrates are ones in which the solvent (e.g., water) molecules are isolated from direct contact with each other by intervening molecules of the organic compound.
- the solvent molecules lie in lattice channels where they are next to other solvent molecules.
- metal-ion coordinated solvates the solvent molecules are bonded to the metal ion.
- the complex When the solvent or water is tightly bound, the complex will have a well-defined stoichiometry independent of humidity. When, however, the solvent or water is weakly bound, as in channel solvates and in hygroscopic compounds, the water or solvent content will depend on humidity and drying conditions. In such cases, non-stoichiometry will be the norm.
- Non-crystalline forms include embodiments which are solids such as waxes and gums as well as embodiments which are liquids such as solutions and melts.
- Crystalline forms include embodiments which represent essentially a single crystal type and embodiments which represent a mixture of polymorphs (i.e. different crystalline types).
- polymorph refers to a particular crystalline form of a chemical compound that can crystallize in different crystalline forms, these forms having different arrangements and/or conformations of the molecules in the crystal lattice.
- polymorphs can have the same chemical composition, they can also differ in composition due the presence or absence of co-crystallized water or other molecules, which can be weakly or strongly bound in the lattice. Polymorphs can differ in such chemical, physical and biological properties as crystal shape, density, hardness, color, chemical stability, melting point, hygroscopicity, suspensibility, dissolution rate and biological availability.
- a polymorph of a compound represented by Formula 1 can exhibit beneficial effects (e.g., suitability for preparation of useful formulations, improved biological performance) relative to another polymorph or a mixture of polymorphs of the same compound represented by Formula 1.
- Preparation and isolation of a particular polymorph of a compound represented by Formula 1 can be achieved by methods known to those skilled in the art including, for example, crystallization using selected solvents and temperatures.
- the compounds herein, and the pharmaceutically acceptable salts thereof may also exist as multicomponent complexes (other than salts and solvates) in which the compound and at least one other component are present in stoichiometric or non-stoichiometric amounts.
- Complexes of this type include clathrates (drug-host inclusion complexes) and co- crystals. The latter are typically defined as crystalline complexes of neutral molecular constituents which are bound together through non-covalent interactions, but could also be a complex of a neutral molecule with a salt.
- Co-crystals may be prepared by melt crystallization, by recrystallization from solvents, or by physically grinding the components together. See, e.g., O. Almarsson and M. J.
- prodrugs refer to compounds that when metabolized in vivo, undergo conversion to compounds having the desired pharmacological activity.
- Prodrugs may be prepared by replacing appropriate functionalities present in pharmacologically active compounds with "pro-moieties"-as described, for example, in H. Bundgaar, Design of Prodrugs (1985).
- prodrugs include ester, ether or amide derivatives of the compounds herein, and their pharmaceutically acceptable salts.
- prodrugs see e.g., T. Higuchi and V. Stella "Pro-drugs as Novel Delivery Systems," ACS Symposium Series 14 (1975) and E. B. Roche ed., Bioreversible Carriers in Drug Design (1987).
- Methods refer to compounds formed in vivo upon administration of pharmacologically active compounds. Examples include hydroxymethyl, hydroxy, secondary amino, primary amino, phenol, and carboxylic acid derivatives of compounds herein, and the pharmaceutically acceptable salts thereof having methyl, alkoxy, tertiary amino, secondary amino, phenyl, and amide groups, respectively.
- Isotopes suitable for inclusion in the compounds herein, and the pharmaceutically acceptable salts thereof include, for example, isotopes of hydrogen, such as 2 H and 3 H; isotopes of carbon, such as U C, 13 C and 14 C; isotopes of nitrogen, such as 13 N and 15 N; isotopes of oxygen, such as 15 0 , 17 0 and 18 0; isotopes of sulfur, such as 35 S; isotopes of fluorine, such as 18 F; isotopes of chlorine, such as 6 C1, and isotopes of iodine, such as 12 Iand 125 I.
- isotopes of hydrogen such as 2 H and 3 H
- isotopes of carbon such as U C, 13 C and 14 C
- isotopes of nitrogen such as 13 N and 15 N
- isotopes of oxygen such as 15 0 , 17 0 and 18 0
- isotopes of sulfur such as 35 S
- isotopic variations may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements.
- certain isotopic variations of the disclosed compounds may incorporate a radioactive isotope (e.g., tritium, H, or 14 C), which may be useful in drug and/or substrate tissue distribution studies.
- positron emitting isotopes such as C, 18 F, 15 0 and 1 N, may be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy.
- PET Positron Emission Topography
- Embodiments of the present invention as described in the Summary of the Invention include those described below.
- Formula 1 includes N-oxides and salts thereof, and reference to "a compound of Formula 1" includes the definitions of substituents specified in the Summary of the Invention unless further defined in the Embodiments.
- Embodiment 1 The method described in the Summary of the Invention for treating a subject suffering from or diagnosed with a disease, disorder, or condition mediated by fatty acid amide hydrolase activity, said method comprising administering to the subject in need of such treatment an effective amount of a compound selected from compounds of Formula 1.
- Embodiment 2 The method of Embodiment 1 wherein A is O or S.
- Embodiment 3 The method of Embodiment 1 wherein A is O or NR 6 .
- Embodiment 3 a The method of Embodiment 3 wherein R 6 is H, Ci -C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, Ci -C4 haloalkyl, C2-C4 haloalkenyl or C2-C4
- Embodiment 4 The method of Embodiment 3a wherein R 6 is H.
- Embodiment 5 The method of any one of Embodiments 1 through 4 wherein A is O or NH.
- Embodiment 6 The method of Embodiment 5 wherein A is O.
- Embodiment 7 The method of Embodiment 5 wherein A is NH.
- Embodiment 8 The method of any one of Embodiments 1 through 7 wherein W is O.
- Embodiment 9. The method of any one of Embodiments 1 through 8 wherein X is CR 2i or N.
- Embodiment 10 The method of Embodiment 9 wherein X is CR 2a .
- Embodiment 10a The method of Embodiment 9 wherein R 2a is H.
- Embodiment 11 The method of Embodiment 9 wherein X is N.
- Embodiment 12 The method of any one of Embodiments 1 through 11 wherein R 1 is selected from U-1 through U-51 as shown in Exhibit 1
- each R v is independently selected from H and R 5a when R v is attached to a carbon atom ring member, and R v is selected from H and R 5 ⁇ when R v is attached to a nitrogen atom ring member (e.g., U-5, U-6, U-9, U-10, U-l 1, U-16, U-17, U-18, U-26, U-27 or U-30), and the bond projecting to the left is bonded to A of Formula 1; k is 0, 1, 2 or 3.
- Embodiment 13 The method of any one of Embodiments 1 through 12 wherein each R 5a is independently halogen, hydroxy, cyano, nitro, Ci -C4 alkyl, C ⁇ -Cg haloalkyl, C 1 -C4 alkoxy, C 1 -C4 haloalkoxy, C 1 -C4 alkylthio, C 1 -C4
- haloalkylthio C 1 -C4 alkylsulfinyl, C 1 -C4 alkylsulfonyl, C 1 -C4 haloalkylsulfinyl, C 1 -C4 haloalkylsulfonyl, C2-Cg dialkylamino, C2-C4 alkylcarbonyl, C2-Cg alkoxycarbonyl or C2-C6 alkylcarbonyloxy.
- Embodiment 14 The method of Embodiment 13 wherein each R 5a is independently halogen, cyano, nitro, C1 -C2 alkyl, Ci -C2 haloalkyl, Ci -C2 alkoxy or Ci -C2 haloalkoxy.
- Embodiment 15 The method of Embodiment 14 wherein each R 5a is independently halogen, nitro, C1 -C2 alkyl, C1 -C2 haloalkyl or C1 -C2 alkoxy.
- Embodiment 16 The method of Embodiment 15 wherein each R 5a is independently bromo, chloro, methyl, trifluoromethyl or methoxy.
- Embodiment 17 The method of Embodiment 16 wherein each R 5a is independently chloro, methyl, trifluoromethyl or methoxy.
- Embodiment 18 The method of any one of Embodiments 1 through 17 wherein each
- R 5 ⁇ is independently Ci -C4 alkyl, Ci -C4 haloalkyl or C2-C4 alkoxyalkyl.
- Embodiment 19 The method of Embodiment 18 wherein each R 5 ⁇ is independently
- Embodiment 20 The method of Embodiment 20 wherein each R 5 ⁇ is methyl.
- Embodiment 21 The method of Embodiment 12 wherein R v is H.
- Embodiment 22 The method of Embodiments 12 wherein k is 0.
- Embodiment 23 The method of any one of Embodiments 12 through 22 wherein R 1 is selected from U-21 and U-37 through U-51.
- Embodiment 24 The method of Embodiment 23 wherein R 1 is selected from U-21 ,
- Embodiment 25 The method of Embodiment 24 wherein R 1 is selected from U-21 ,
- Embodiment 26 The method of any one of Embodiments 1 through 25 wherein each
- R 2 is independently C1 -C2 alkyl or C 1 -C2 haloalkyl.
- Embodiment 27 The method of any one of Embodiments 1 through 26 wherein n is 0 or 1.
- Embodiment 28 The method of Embodiment 27 wherein n is 0.
- Embodiment 29 The method of any one of Embodiments 1 through 28 wherein each
- R 3 when taken alone (i.e. not taken together with R 8a or R 8 ⁇ ) is independently cyano or C1-C3 alkyl.
- Embodiment 30 The method of Embodiment 29 wherein each R 3 when taken alone is independently cyano or Ci -C2 alkyl.
- Embodiment 31 The method of any one of Embodiments 1 through 31 wherein each
- R 3 is taken alone (i.e. not taken together with R 8a or R 8 ⁇ ).
- Embodiment 32 The method of any one of Embodiments 1 through 31 wherein m is 0 or 1.
- Embodiment 33 The method of Embodiment 32 wherein m is 0.
- Embodiment 34 The method of any one of Embodiments 1 through 33 wherein R 4 is benzyl, phenyl or naphthalenyl, each optionally substituted with up to 3 substituents independently selected from R 8a ; or pyridinyl, thienyl, pyrazolyl, triazolyl or imidazolyl, each optionally substituted with up to 3 substituents independently selected from R 8a on carbon atom ring members and R 8 ⁇ on a nitrogen atom ring member.
- R 4 is benzyl, phenyl or naphthalenyl, each optionally substituted with up to 3 substituents independently selected from R 8a ; or pyridinyl, thienyl, pyrazolyl, triazolyl or imidazolyl, each optionally substituted with up to 3 substituents independently selected from R 8a on carbon atom ring members and R 8 ⁇ on a nitrogen atom ring member.
- Embodiment 35 The method of Embodiment 34 wherein R 4 is benzyl or phenyl, each optionally substituted with up to 3 substituents independently selected from R 8a or pyridinyl or thienyl, each optionally substituted with up to 3 substituents independently selected from R 8a on carbon atom ring members.
- Embodiment 36 The method of Embodiment 35 wherein R 4 is phenyl optionally substituted with up to 3 substituents independently selected from R 8a .
- Embodiment 37 The method of Embodiment 36 wherein R 4 is phenyl optionally substituted with up to 2 substituents independently selected from R 8a .
- Embodiment 38 The method of Embodiment 37 wherein R 4 is phenyl.
- Embodiment 39 The method of any one of Embodiments 1 through 37 wherein each R8a w hen taken alone (i.e. not taken together with R 3 ) is independently halogen hydroxy, amino, cyano, nitro, Ci-C ⁇ alkyl, Ci-C ⁇ haloalkyl, Ci-C ⁇ alkoxy, Ci -C3 haloalkoxy, Ci -C3 alkylthio or C1-C3 haloalkylthio.
- Embodiment 40 The method of Embodiment 41 wherein each R 8a when taken alone independently halogen, methyl, halomethyl or methoxy.
- Embodiment 41 The method of any one of Embodiments 1 through 40 wherein each
- R 8a is taken alone (i.e. not taken together with R 3 ).
- Embodiment 42 The method of any one of Embodiments 1 through 34 wherein each
- R8b w en taken alone is independently C1-C3 alkyl.
- Embodiment 43 The method of Embodiment 42 wherein each R 8 ⁇ when taken alone
- Embodiment 44 The method of any one of Embodiments 1 through 43 wherein each
- R 8 ⁇ is taken alone (i.e. not taken together with R 3 ).
- Embodiment 45 The method of any one of Embodiments 1 through 44 wherein G is selected from G-1 through G-48 as shown in Exhibit 2
- R Y is selected from H and R 7a , when R Y is attached to a carbon atom ring member, and R Y is selected from H and R 7 ⁇ when R Y is attached to a nitrogen atom ring member, and the bond projecting to the left is bonded to X and the bond projecting to the right is bonded to the isoxazole ring in Formula 1; q is 0 or 1.
- Embodiment 46 The method of Embodiment 45 wherein R Y is H.
- Embodiment 47 The method of Embodiment 45 wherein q is 0.
- Embodiment 48 The method of any one of Embodiments 45 through 47 wherein G is selected from G-25 through G-34 and G-43 through G-48.
- Embodiment 49 The method of Embodiment 48 wherein G is selected from G-26,
- Embodiments of this invention can be combined in any manner, and the descriptions of variables in the embodiments pertain not only to methods of treatment but also to the compounds of Formula 1, starting compounds and intermediate compounds useful for preparing the compounds of Formula 1 and to the compositions comprising the compounds of Formula 1 unless further defined in the Embodiments.
- Combinations of Embodiments 1-49 are illustrated by:
- Embodiment Al The method described in the Summary of the Invention for treating a subject suffering from or diagnosed with a disease, disorder, or condition mediated by fatty acid amide hydrolase activity, said method comprising administering to the subject in need of such treatment an effective amount of a compound selected from compounds of Formula 1 wherein
- A is O or NH
- R 1 is selected from U-l through U-51 as shown in Exhibit 1 wherein each R v is independently selected from H and R 5a when R v is attached to a carbon atom ring member, and R v is selected from H and R 5 ⁇ when R v is attached to a nitrogen atom ring member, and the bond projecting to the left is bonded to A of Formula 1;
- k 0, 1, 2 or 3;
- R 4 is benzyl, phenyl or naphthalenyl, each optionally substituted with up to 3 substituents independently selected from R 8a ; or pyridinyl, thienyl, pyrazolyl, triazolyl or imidazolyl, each optionally substituted with up to 3 substituents independently selected from R 8a on carbon atom ring members and R 8 ⁇ on a nitrogen atom ring member;
- G is selected from G-l through G-48 as shown in Exhibit 2 wherein R Y is selected from H and R 7a when R Y is attached to a carbon atom ring member, and R Y is selected from H and R 7 ⁇ when R Y is attached to a nitrogen atom ring member, and the bond projecting to the left is bonded to X and the bond projecting to the right is bonded to the isoxazole ring in Formula 1; and
- q 0 or 1.
- Embodiment A2 A method of Embodiment A 1 wherein
- A is O
- W is O
- X is CR 2a ;
- R 1 is selected from U-21 and U-37 through U-51 ;
- each R 2 is independently C1-C2 alkyl or C1-C2 haloalkyl
- R 2a is H
- each R 3 is independently cyano or -C3 alkyl
- R 4 is benzyl or phenyl, each optionally substituted with up to 3 substituents independently selected from R 8a ; or pyridinyl or thienyl, each optionally substituted with up to 3 substituents independently selected from R 8a on carbon atom ring members;
- each R 5a is independently halogen, hydroxy, cyano, nitro, -C4 alkyl, C j -Cg haloalkyl, -C4 alkoxy, -C4 haloalkoxy, -C4 alkylthio, -C4 haloalkylthio, -C4 alkylsulfinyl, -C4 alkylsulfonyl, C1-C4 haloalkylsulfinyl, C1-C4 haloalkylsulfonyl, C 2 -C 8 dialkylamino, C 2 -C 4 alkylcarbonyl, C2-Cg alkoxycarbonyl or C2-Cg alkylcarbonyloxy;
- G is selected from G-25 through G-34 and G-43 through G-48;
- each R 8a is independently halogen, hydroxy, amino, cyano, nitro, -C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 alkylthio or C1-C3 haloalkylthio;
- n 0 or 1 ;
- Embodiment A3 A method of Embodiment A2 wherein
- R 1 is selected from U-21 , U-37, U-38, U-39, U-42, U-44, U-50 and U-51 ;
- R 4 is a phenyl optionally substituted with up to 3 substituents independently selected from R 8a ;
- each R 5a is independently halogen, cyano, nitro, -C2 alkyl, C1-C2 haloalkyl, C1-C2 alkoxy or C1-C2 haloalkoxy;
- n 0;
- m 0 or 1.
- Embodiment A4 A method of Embodiment A3 wherein
- R 1 is selected from U-21 , U-50 and U-51 ;
- R 3 is cyano or Ci-C 2 alkyl; each R 5a is independently halogen, nitro, Ci -C2 alkyl, Ci -C2 haloalkyl or
- G is selected from G-26, G-34, G-43 and G-47.
- Embodiment A5. A method of Embodiment A4 wherein
- R 1 is U-50
- R 4 is a phenyl
- each R 5a is independently bromo, chloro, methyl, trifluoromethyl or methoxy;
- G is G-26;
- Specific embodiments include a method described in the Summary of the Invention for treating a subject suffering from or diagnosed with a disease, disorder, or condition mediated by fatty acid amide hydrolase activity, said method comprising administering to the subject in need of such treatment an effective amount of a compound of Formula 1 selected from the group consisting of:
- Embodiments of the present invention also include Embodiments B l through B35 described below.
- Embodiment B 1. A compound of Formula 1 wherein
- A is O or S
- W is O or S
- X is CR 2a or N
- R 1 is phenyl, naphthalenyl or l ,2-benzisoxazol-3-yl, each optionally substituted with up to 3 substituents independently selected from R 5a ; or a 5- to 6-membered heteroaromatic ring, the ring containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, the ring optionally substituted with up to 3 substituents independently selected from R 5a on carbon atom ring members and R 5 ⁇ on nitrogen atom ring members;
- each R 2 is independently halogen, cyano, hydroxy, Ci -C2 alkyl, Ci-C 2 haloalkyl or C1 -C2 alkoxy;
- R 2a is H, halogen, cyano, hydroxy, Ci -C2 alkyl, Ci -C2 haloalkyl or Ci -C2 alkoxy; each R 3 is independently halogen, cyano, Ci -C3 alkyl or Ci -C3 haloalkyl;
- R 4 is Ci -C alkyl, Ci -C haloalkyl, C 3 -C 8 cycloalkyl, C 3 -C 8 halocycloalkyl, C 4 -C 10 alkylcycloalkyl, C 4 -C 10 cycloalkylalkyl, C 2 -C 8 alkoxyalkyl, C 2 -C 8 haloalkoxyalkyl, C4-C10 cycloalkoxyalkyl, C3-C 8 alkoxyalkoxyalkyl, C2-Cg alkylthioalkyl, C2-Cg alkylsulfinylalkyl, C2-Cg alkylsulfonylalkyl, C2-Cg alkylaminoalkyl, C2-Cg haloalkylaminoalkyl, C3-Cg dialkylaminoalkyl, C4-C10 cycloalkylaminoalkyl, C j -Cg
- each R 5a is independently halogen, hydroxy, amino, cyano, nitro, C1-C4 alkyl, C j -Cg haloalkyl, C 3 -C 6 cycloalkyl, C 3 -C 6 halocycloalkyl, C 2 -C 4 alkoxyalkyl, -C4 hydroxyalkyl, -C4 alkoxy, C1-C4 haloalkoxy, -C4 alkylthio, C1-C4 haloalkylthio, -C4 alkylsulfinyl, -C4 alkylsulfonyl, C1-C4 haloalkylsulfinyl, 1-C4 haloalkylsulfonyl, C1-C4 alkylamino, C 2 -C 8 dialkylamino, C 2 -C 4 alkylcarbonyl, C2-Cg alkoxycarbonyl, C2-Cg al
- each R 5b is independently -C4 alkyl, C3-C4 alkenyl, C3-C4 alkynyl, C 3 -C 6
- cycloalkyl -C4 haloalkyl, C3-C4 haloalkenyl, C3-C4 haloalkynyl, C 3 -C 6 halocycloalkyl or C2-C4 alkoxyalkyl;
- G is a 5-membered heteroaromatic ring, the ring containing ring members selected from carbon atoms and 1 to 3 heteroatoms independently selected from up to 2 O, up to 2 S and up to 3 N atoms, the ring optionally substituted with up to 1 substituent selected from R 7a on a carbon atom and R 7 ⁇ on a nitrogen atom;
- R 7a is halogen, cyano, C1-C2 alkyl or C1-C2 haloalkyl
- R 7b is C r C 2 alkyl or C r C 2 haloalkyl
- each R 8a is independently halogen, hydroxy, amino, cyano, nitro, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, C1-C4
- C1-C4 haloalkylsulfonyl C1-C4 alkylamino, C 2 -C 6 dialkylamino, C 2 -C 4 alkylcarbonyl, C2-Cg alkoxycarbonyl, C2-Cg alkylaminocarbonyl or C3-Cg dialkylaminocarbonyl; or
- R 8a and R 3 are taken together with the atoms to which they are attached to form a 5- to 7-membered ring, the ring containing ring members selected from carbon atoms and up to 2 heteroatoms independently selected from up to 1 O, up to 1 S and up to 1 N, wherein up to 2 carbon atom ring members are
- each R 8 ⁇ is independently Ci -C4 alkyl or C 1 -C4 haloalkyl; or
- R 8 ⁇ and R 3 are taken together with the atoms to which they are attached to form a 5- to 7-membered ring, the ring containing ring members selected from carbon atoms and up to 2 heteroatoms independently selected from up to 1 O, up to 1 S and up to 1 N, wherein up to 2 carbon atom ring members are
- each R 9a is independently halogen, Ci -C4 alkyl, C i -C4 haloalkyl, C 1 -C4 alkoxy,
- R 9b is C r C 4 alkyl or C r C 4 haloalkyl
- R 10 is independently H, C i -C4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, Ci -C4 haloalkyl, C2-C4 haloalkenyl, C2-C4 haloalkynyl, C2-C4 alkoxyalkyl, C2-C4 alkylcarbonyl, C 2 -C 4 haloalkylcarbonyl, C1 -C4 alkylsulfonyl or C 1 -C4 haloalkylsulfonyl;
- n 0, 1 or 2;
- n 0, 1 or 2;
- Embodiment B2 A compound of Embodiment Bl wherein A is O.
- Embodiment B A compound of Embodiment Bl or B2 wherein W is O.
- Embodiment B4 A compound of any one of Embodiments Bl through B3 wherein X is CR 2a or N.
- Embodiment B5. A compound of Embodiment B4 wherein X is N.
- Embodiment B6 A compound of Embodiment B4 wherein X is CR 2a .
- Embodiment B7 A compound of Embodiment B6 whereinR 2a is H.
- Embodiment B8 A compound of any one of Embodiments Bl through B7 wherein R 1 is selected from U-l through U-51 as shown in Exhibit 1 Exhibit 1
- each R v is independently selected from H and R 5a when R v is attached to a carbon atom ring member, and R v is selected from H and R 5 ⁇ when R v is attached to a nitrogen atom ring member (e.g., U-5, U-6, U-9, U-10, U-l 1, U-16, U-17, U-l 8, U-26, U-27 or U-30), and the bond projecting to the left is bonded to A of Formula 1; k is 0, 1, 2 or 3.
- Embodiment B9 A compound of any one of Embodiments Bl through B8 wherein each R 5a is independently halogen, hydroxy, cyano, nitro, -C4 alkyl, C ⁇ -Cg haloalkyl, C1-C4 alkoxy, -C4 haloalkoxy, C1-C4 alkylthio, C1-C4
- haloalkylthio C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, C1-C4 haloalkylsulfinyl, C1-C4 haloalkylsulfonyl, C2-Cg dialkylamino, C2-C4 alkylcarbonyl, C2-C6 alkoxycarbonyl or C2-C6 alkylcarbonyloxy.
- Embodiment BIO A compound of Embodiment B9 wherein each R 5a is independently halogen, cyano, nitro, C1-C2 alkyl, C1-C2 haloalkyl, C1-C2 alkoxy or C1-C2 haloalkoxy.
- Embodiment B 1 1.
- Embodiment B12 A compound of any one of Embodiment B l 1 wherein each R 5a is independently chloro, methyl, trifluoromethyl or methoxy
- Embodiment B13 A compound any one of Embodiments Bl through B12 wherein each
- R 5 ⁇ is independently Ci -C4 alkyl, Ci -C4 haloalkyl or C2-C4 alkoxyalkyl.
- Embodiment B 14 A compound of Embodiment B13 wherein each R 5 ⁇ is
- Embodiment B 15 A compound of Embodiment B14 wherein each R 5 ⁇ is methyl.
- Embodiment B 16 A compound of Embodiments B8 wherein each R v is H.
- Embodiment B 17. A compound of Embodiments B8 wherein each k is 0.
- Embodiment B18 A compound of any one of Embodiments B8 through B17 wherein
- R 1 is selected from U-21 and U-37 through U-51.
- Embodiment B 19 A compound of Embodiment B18 wherein R 1 is selected from U-21 , U-37, U-38, U-39, U-42, U-44, U-50 and U-51.
- Embodiment B20 A compound of Embodiment B19 wherein R 1 is selected from U-21 ,
- Embodiment B21 A compound of any one of Embodiments Bl through B20 wherein each R 2 is independently C i -C2 alkyl or Ci -C2 haloalkyl.
- Embodiment B22 A compound of any one of Embodiments Bl through B21 wherein n is 0 or 1.
- Embodiment B23 A compound of Embodiment B22 wherein n is 0.
- Embodiment B24 A compound of any one of Embodiments Bl through B23 wherein each R 3 when taken alone (i.e. not taken together with R 8a or R 8 ⁇ ) is
- Embodiment B25 A compound of Embodiment B24 wherein each R 3 when taken
- Embodiment B26 A compound of any one of Embodiments Bl through B25 wherein each R 3 is taken alone (i.e. not taken together with R 8a or R 8 ⁇ ).
- Embodiment B27 A compound of any one of Embodiments Bl through B26 wherein m when is 0 or 1.
- Embodiment B28 A compound of any one of Embodiments Bl through B27 wherein R 4 is benzyl, phenyl or naphthalenyl, each optionally substituted with up to 3 substituents independently selected from R 8a ; or pyridinyl, thienyl, pyrazolyl, triazolyl or imidazolyl, each optionally substituted with up to 3 substituents independently selected from R 8a on carbon atom ring members and R 8 ⁇ on a nitrogen atom ring member.
- R 4 is benzyl, phenyl or naphthalenyl, each optionally substituted with up to 3 substituents independently selected from R 8a ; or pyridinyl, thienyl, pyrazolyl, triazolyl or imidazolyl, each optionally substituted with up to 3 substituents independently selected from R 8a on carbon atom ring members and R 8 ⁇ on a nitrogen atom ring member.
- Embodiment B30 A compound of Embodiment B29 wherein R 4 is a phenyl optionally substituted with up to 3 substituents independently selected from R 8a .
- Embodiment B31 A compound of any one of Embodiments Bl through B30 wherein each R 8a when taken alone (i.e. not taken together with R 3 ) is independently halogen, hydroxy, amino, cyano, nitro, Ci-C ⁇ alkyl, Ci-C ⁇ haloalkyl, Ci-C ⁇ alkoxy, C 1 -C3 haloalkoxy, C1 -C3 alkylthio or C1-C3 haloalkylthio.
- Embodiment B32 A compound of Embodiment B31 wherein each R 8a when taken alone is independently halogen, methyl, halomethyl or methoxy.
- Embodiment B33 A compound of any one of Embodiments Bl through B32 wherein each R 8a is taken alone (i.e. not taken together with R 3 ).
- Embodiment B34 A compound of any one of Embodiments B l through B33 wherein G is selected from G-1 through G-48 as shown in Exhibit 2
- R Y is selected from H and R 7a , when R Y is attached to a carbon atom ring member, and R Y is selected from H and R 7 ⁇ when R Y is attached to a nitrogen atom ring member, and the bond projecting to the left is bonded to X and the bond projecting to the right is bonded to the isoxazole ring in Formula 1; q is 0 or 1;
- Embodiment B35 A compound of Embodiment B34 wherein G is selected from G-25 through G-34 and G-43 through G-48.
- Embodiment B36 A compound of Embodiment B35 wherein G is selected from G-26, G-34, G-43 and G-47.
- Embodiment B37 A compound of Embodiment B36 wherein R Y is H.
- Embodiment B38 A compound of any one of Embodiment B31 wherein q is 0.
- Embodiment CI A compound of Embodiment B 1 wherein
- R 1 is selected from U-l through U-51 as shown in Exhibit 1 wherein each R v is independently selected from H and R 5a when R v is attached to a carbon atom ring member, and R v is selected from H and R 5 ⁇ when R v is attached to a nitrogen atom ring member, and the bond projecting to the left is bonded to A of Formula 1;
- k 0, 1, 2 or 3;
- R 4 is benzyl, phenyl or naphthalenyl, each optionally substituted with up to 3 substituents independently selected from R 8a ; or pyridinyl, thienyl, pyrazolyl, triazolyl or imidazolyl, each optionally substituted with up to 3 substituents independently selected from R 8a on carbon atom ring members and R 8 ⁇ on a nitrogen atom ring member;
- G is selected from G-l through G-48 as shown in Exhibit 2 wherein R Y is selected from H and R 7a when R Y is attached to a carbon atom ring member, and R Y is selected from H and R 7 ⁇ when R Y is attached to a nitrogen atom ring member, and the bond projecting to the left is bonded to X and the bond projecting to the right is bonded to the isoxazole ring in Formula 1; and
- q 0 or 1.
- Embodiment C2 A compound of Embodiment CI wherein
- A is O
- W is O
- X is CR 2a ;
- R 1 is selected from U-21 and U-37 through U-51;
- each R 2 is independently C1-C2 alkyl or C1-C2 haloalkyl
- R 2a is H; each R 3 is independently cyano or -C3 alkyl;
- R 4 is benzyl or phenyl, each optionally substituted with up to 3 substituents independently selected from R 8a ; or pyridinyl or thienyl, each optionally substituted with up to 3 substituents independently selected from R 8a on carbon atom ring members;
- each R 5a is independently halogen, hydroxy, cyano, nitro, Ci -C4 alkyl, C j -Cg haloalkyl, C1 -C4 alkoxy, C1 -C4 haloalkoxy, C1 -C4 alkylthio, C1 -C4 haloalkylthio, C1 -C4 alkylsulfinyl, C1 -C4 alkylsulfonyl, C 1 -C4 haloalkylsulfinyl, C 1 -C4 haloalkylsulfonyl, C 2 -C 8 dialkylamino, C 2 -C 4 alkylcarbonyl, C2-Cg alkoxycarbonyl or C2-Cg alkylcarbonyloxy;
- G is selected from G-25 through G-34 and G-43 through G-48; each R 8a is independently halogen, hydroxy, amino, cyano, nitro, Ci -C3 alkyl, C 1 -C3 haloalkyl, C1 -C3 alkoxy, C 1 -C3 haloalkoxy, C1 -C3 alkylthio or C 1 -C3 haloalkylthio;
- n 0 or 1 ;
- Embodiment C3 A compound of Embodiment C2 wherein
- R 1 is selected from U-21, U-37, U-38, U-39, U-42, U-44, U-50 and U-51; each R 5a is independently halogen, cyano, nitro, Ci -C2 alkyl, Ci -C2
- R 4 is a phenyl ring optionally substituted with up to 3 substituents independently selected from R 8a ;
- n 0;
- m 0 or 1.
- Embodiment C4 A compound of Embodiment C3 wherein
- R 1 is selected from U-21, U-50 and U-51;
- R 3 is cyano or Ci -C2 alkyl
- each R 5a is independently halogen, nitro, Ci -C2 alkyl, Ci -C2 haloalkyl or
- G is selected from G-26, G-34, G-43 and G-47.
- Embodiment C5. A compound of Embodiment C4 wherein
- R 1 is U-50
- R 4 is a phenyl
- each R 5a is independently bromo, chloro, methyl, trifluoromethyl or methoxy;
- G is G-26;
- Specific embodiments include compounds of Formula 1 selected from the group consisting of: phenyl-4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-l- piperidinecarboxylate; and
- compounds of Formula 1 wherein A is O, S or NR 6 and R 6 is other than H can be prepared by coupling a chloroformate, thiochloroformate, carbamoyl chloride or thiocarbamoyl chloride of Formula 2 with an amine of Formula 3 in the presence of an acid scavenger.
- Typical acid scavengers include amine bases such as triethylamine, N,N-diisopropylethylamine and pyridine.
- Other scavengers include hydroxides such as sodium and potassium hydroxide and carbonates such as sodium carbonate and potassium carbonate.
- Acid salts of the Formula 3 amines can also be used in this reaction, provided that at least 2 equivalents of the acid scavenger is present.
- Typical acids used to form salts with amines include hydrochloric acid, oxalic acid and trifluoroacetic acid.
- carbamates and ureas of Formula 1 wherein W is O can be converted to thiocarbamates and thioureas of Formula 1 wherein W is S using a variety of standard thiating reagents such as phosphorus pentasulfide or 2,4-bis(4-methoxyphenyl)-l,3-dithia-2,4-diphosphetane-2,4- disulfide (Lawesson's reagent).
- the chloroformates, thiochloroformates, carbamoyl chlorides or thiocarbamoyl chlorides of Formula 2 are either known or can be prepared by methods known to one skilled in the art.
- A is O, S or NR 6 and R 6 is not H
- Compounds of Formula 1 can also be prepared by the reaction of an amine, thiol or hydroxyl compound of Formula 4 with a carbamoyl or thiocarbamoyl chloride or imidazole of Formula 5 as shown in Scheme 2.
- Y is chlorine
- the reaction is typically carried out in the presence of an acid scavenger.
- Typical acid scavengers include amine bases such as triethylamine, N,N-diisopropylethylamine and pyridine.
- Other scavengers include hydroxides such as sodium and potassium hydroxide and carbonates such as sodium carbonate and potassium carbonate.
- the carbamoyl or thiocarbamoyl chlorides of Formula 5 can be prepared from amines of Formula 3 by treatment with phosgene or thiophosgene, respectively, or their equivalents, while carbamoyl or thiocarbamoyl imidazoles of Formula 5 (wherein Y is imidazol-l-yl) can be prepared from amines of Formula 3 by treatment with ⁇ , ⁇ -carbonyldiimidazole or 1 , l'-thiocarbonyldiimidazole, respectively, according to general methods known to one skilled in the art.
- Thiocarbamates can also be formed by palladium-catalyzed reactions of disulfides, amines and carbon monoxide as described by Y. Nishiyama, et al, J. Org. Chem., 2005, 70, 2551-2554.
- the amine, thiol or hydroxyl compounds of Formula 4 are either known or can be prepared by one skilled in the art.
- W is O or S and Y is CI or imidazol-l-yl
- Compounds of Formula 1 wherein A is NH can be prepared by reaction of an amine of Formula 3 with an isocyanate or isothiocyanate, respectively, of Formula 6 as depicted in Scheme 3. This reaction is typically carried out at ambient temperature in an aprotic solvent such as dichloromethane or acetonitrile.
- Certain compounds of Formula 1 wherein X is CR 2 and G is linked to the ring containing X via a nitrogen atom, can be prepared by displacement of an appropriate leaving group Y 1 on the ring containing the X of Formula 7 with a nitrogen-containing heterocycle of Formula 8 in the presence of a base as depicted in Scheme 4.
- Suitable bases include sodium hydride or potassium carbonate, and the reaction is carried out in a solvent such as N,N-dimethylformamide or acetonitrile at 0 to 80 °C.
- Suitable leaving groups in the compounds of Formula 7 include bromide, iodide, mesylate (OS(0) 2 CH 3 ), triflate (OS(0) 2 CF 3 ) and the like, and compounds of Formula 7 can be prepared from the corresponding compounds wherein Y 1 is OH, using general methods known in the art.
- W is O or S;
- X is CR 2 and Y 1 is Br, I, OS(0) 2 Me or OS(0) 2 CF 3
- Compounds of Formula 1 wherein X is N can be prepared by reaction of a compound of Formula 9 with a heterocyclic halide or triflate (OS(0)2CF3) of Formula 10 as shown in Scheme 5. The reaction is carried out in the presence of a base such as potassium carbonate in a solvent such as dimethylsulfoxide, N,N-dimethylformamide or acetonitrile at 0 to 80 °C.
- a base such as potassium carbonate
- a solvent such as dimethylsulfoxide, N,N-dimethylformamide or acetonitrile at 0 to 80 °C.
- Compounds of Formula 10 wherein Y 1 is triflate can be prepared from corresponding compounds wherein Y 1 is OH by methods known to one skilled in the art.
- W is O or S; X is N and Y 1 is Br, I, OS(0) 2 Me or OS(0) 2 CF 3
- Compounds of Formula 1 can also be prepared by reaction of a suitably functionalized compound of Formula 11 with a suitably functionalized compound of Formula 12 as shown in Scheme 6.
- the functional groups Y 2 and Y 3 are selected from, but not limited to, moieties such as aldehydes, ketones, esters, acids, amides, thioamides, nitriles, amines, alcohols, thiols, hydrazines, oximes, amidines, amideoximes, olefins, acetylenes, halides, alkyl halides, methanesulfonates, trifluoromethanesulfonates, boronic acids, boronates, and the like, which under the appropriate reaction conditions, will allow the construction of the various heterocyclic rings G.
- reaction of a compound of Formula 11 where Y 2 is a thioamide group with a compound of Formula 12 where Y 3 is a bromoacetyl group will give a compound of Formula 1 where G is a thiazole ring.
- the synthetic literature describes many general methods for forming 5-membered heteroaromatic rings (e.g., G-l through G-48 of Exhibit 2); see, for example, Comprehensive Heterocyclic Chemistry, Vol. 4-6, A. R. Katritzky and C. W. Rees editors, Pergamon Press, New York, 1984; Comprehensive Heterocyclic Chemistry II, Vol. 2-4, A. R. Katritzky, C. W. Rees, and E. F.
- Compounds of Formula 1 where G is linked to the isoxazoline ring via a nitrogen atom can be prepared by displacement of halogen leaving group Y 4 on an isoxazoline of Formula 14 with a compound of Formula 13 in the presence of a base as depicted in Scheme 7.
- Suitable bases include sodium hydride or potassium carbonate, and the reaction is carried out in a solvent such as N,N-dimethylformamide or acetonitrile at temperatures between about 0 to 80 °C.
- Compounds of Formula 14 are known or can be prepared by reacting a dihaloformaldoxime with an appropriate vinyl compound as known in the art.
- G is a nitrogen heterocycle containing a free NH and Y 4 is halogen
- Compounds of Formula 1 can also be prepared by reaction of a chloro oxime of Formula 15 with a olefin of Formula 16 in the presence of a base as shown in Scheme 8. The reaction proceeds via an intermediate nitrile oxide.
- Scheme 8 General procedures for cycloaddition of nitrile oxides with olefins are well documented in the chemical literature. For relevant references see Lee, Synthesis 1982, 6, 508-509 and Kanemasa et al, Tetrahedron 2000, 56, 1057-1064 as well as references cited within.
- the chloro oximes of Formula 15 can be prepare by treating the corresponding aldehyde with hydroxylamine followed by chlorination with a suitable chlorinating agent such as N-chlorosuccinamide, as known to one skilled in the art.
- a suitable chlorinating agent such as N-chlorosuccinamide, as known to one skilled in the art.
- the compounds of Formula 16 are known or can be prepared by general methods known in the art.
- Amines of Formula 3 can be prepared from compounds of Formula 17 wherein Y 5 is an amine protecting group via a deprotection reaction as shown in Scheme 9.
- Y 5 is an amine protecting group via a deprotection reaction as shown in Scheme 9.
- a wide array of amine protecting groups are suitable for the method of Scheme 9 (see, for example, T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 2nd ed.; Wiley: New York, 1991), and the choice of the appropriate protecting groups will be apparent to one skilled in chemical synthesis.
- the amine of Formula 3 can be isolated as its acid salt or the free amine by general methods known in the art.
- Thioamides of Formula 18 are particularly useful intermediates for preparing compounds of Formula 1 and 17.
- a thioamide of Formula 18 can be prepared by the addition of hydrogen sulfide to the corresponding nitrile of Formula 19 wherein X is a carbon atom and Y 7 is a nitrile moiety as shown in Scheme 10.
- the methods of Scheme 10 can be carried out by contacting a compound of Formula 19 with hydrogen sulfide in the presence of an amine such as pyridine, diethylamine or diethanolamine.
- hydrogen sulfide can be used in the form of its bisulfide salt with an alkali metal or ammonia. This type of reaction is well documented in the literature see; for example, European Patent EP 696581.
- a thioamide of Formula 18 can be prepared by the reaction of a compound of Formula 19 wherein X is a nitrogen atom and Y 7 is H and thiocarbonyl diimidazole followed by treatment with ammonia as described by J. L. Collins, et al, J. Med. Chem. 1998, 41, 5037-5054.
- Halomethyl isoxazoline ketones of Formula 24 are also particularly useful intermediates for preparing certain chiral compounds of Formula 1.
- Halomethyl isoxazoline ketones of Formula 24 can be prepared by the multi-step reaction sequences shown in Scheme 11.
- Scheme 11 can also be practiced without the use of a resolving agent, so that a compound of Formula 21 is converted directly to a racemic analog of Formula 20a, which can then be used to prepare racemic analogs of Formulae 23 and 24 and certain racemic compounds of Formula 1.
- R is C 2 -C 8 dialkylamino, C 2 -Cg haloalkylamino, 1 -piperidinyl, 1 -pyrrolidinyl or 4-morpholinyl; and Y 1 is CI, Br or I
- the preparation of racemic carboxylic acids of Formula 21 can be accomplished according to the well-known methods of basic or acidic hydrolysis of the corresponding compounds of Formula 20, preferably using a slight excess of sodium hydroxide in a water- miscible co-solvent such as methanol or tetrahydrofuran at about 25 to 45 °C.
- the product can be isolated by adjusting the pH of the reaction mixture to about 1 to 3 and then filtration or extraction, optionally after removal of the organic solvent by evaporation.
- the racemic carboxylic acids of Formula 21 can be resolved by classical fractional crystallization of diastereomeric salts of suitable chiral amine bases such as cinchonine, dihydrocinchonine or a mixture thereof.
- suitable chiral amine bases such as cinchonine, dihydrocinchonine or a mixture thereof.
- a cinchonine-dihydrocinchonine mixture in about a 85: 15 ratio is particularly useful, as it provides, for example, the (i?)-configured carboxylic acids of Formula 22, wherein R 4 is a substituted phenyl group, as the less soluble salt.
- R 4 is a substituted phenyl group
- these chiral amine bases are readily available on a commercial scale.
- the halomethyl ketones of Formula 24 can be prepared by first reacting the corresponding amides of Formula 20, either as pure enantiomers (i.e.
- the halomethyl ketones of Formula 24 can be purified by crystallization from a solvent such as hexanes or methanol, or can be used without further purification in the condensation reaction with thioamides of Formula 18 to form compounds of Formula 1 where G is a thiazole ring.
- the isoxazoline carboxamides of Formula 20 can be prepared by cycloaddition of the corresponding hydroxamoyl chlorides of Formula 25 with olefin derivatives of Formula 26, as shown in Scheme 12.
- R 30 is C 2 -Cg dialkylamino, C 2 -Cg haloalkylamino, 1 -piperidinyl, 1 -pyrrolidinyl or 4-morpholinyl
- all three reacting components are contacted so as to minimize hydrolysis or dimerization of the hydroxamoyl chloride of Formula 25.
- the base which can either be a tertiary amine base such as triethylamine or an inorganic base such as an alkali metal or alkaline- earth carbonate, bicarbonate or phosphate, is mixed with the olefin derivative of Formula 26, and the hydroxamoyl chloride of Formula 25 is added gradually at a temperature at which the cycloaddition proceeds at a relatively rapid rate, typically between 5 and 25 °C.
- the base can be added gradually to the other two components (the compounds of Formulae 25 and 26). This alternative procedure is preferable when the hydroxamoyl chloride of Formula 25 is substantially insoluble in the reaction medium.
- the solvent in the reaction medium can be water or an inert organic solvent such as toluene, hexane or even the olefin derivative used in excess.
- the product can be separated from the salt co-product by filtration or washing with water, followed by evaporation of the solvent.
- the crude product can be purified by crystallization, or the crude product can be used directly in the methods of Scheme 11.
- Compounds of Formula 20 are useful precursors to the corresponding methyl ketones of Formula 23 and halomethyl ketones of Formula 24, and are also useful for preparing the resolved enantiomers of the compounds of Formulae 23 and 24 by hydrolysis, resolution, methyl ketone synthesis and halogenation, as shown in Scheme 11.
- Step A Preparation of 1 , 1 -dimethylethyl 4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2- thiazolyl]- 1 -piperidinecarboxylate
- Step B Preparation of 4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-
- reaction mixture was concentrated under reduced pressure and partitioned between ethyl acetate and saturated aqueous sodium bicarbonate.
- organic layer was dried (MgS0 4 ) and concentrated to give the title compound as a clear oil (0.31 g), which solidified on standing.
- Step C Preparation of phenyl 4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-
- Step A Preparation of 1 , 1 -dimethylethyl 4-(aminothioxomethyl)- 1 -piperazine- carboxylate
- Step C Preparation of 2-chloro-l -(4,5 -dihydro-5-phenyl-3-isoxazolyl)ethanone
- Step D Preparation of 1,1-dimethylethyl 4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-
- Step E Preparation of l-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]- piperazine hydrochloride
- Step F Preparation of 4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-N-(2,5- dimethylphenyl)- 1 -piperazinecarboxamide
- Step E the product of Step E) (0.16 g, 0.509 mmol) in tetrahydrofuran was added dropwise at 0 °C and the mixture was then stirred at room temperature for 2 h. The mixture was concentrated in vacuum, and the residue was dissolved in EtOAc (50 mL), washed with water (50 mL) and brine (50 mL), dried over Na 2 S0 4 and concentrated under reduced pressure. The crude product was purified by column chromatography (10% MeOH / CHCI3) to provide the title compound as a white solid (0.17 g).
- Step B Preparation of 4,5-dihydro-5-phenyl-3-isoxazolecarboxylic acid
- the crude product was extracted into ethyl acetate (200 mL).
- the ethyl acetate solution was concentrated under reduced pressure, and the residue was triturated with hexanes.
- the resulting precipitate was filtered, washed with hexanes (2 x 20 mL), and dried under vacuum to give 46.5 g of the title compound as a solid.
- Step C Preparation of the cinchonine salt of (5i?)-4,5-dihydro-5-phenyl-3-isoxazole- carboxylic acid
- the filter cake was washed twice with 10 mL of 25% methanol in water, and air dried to give 8.52 g of the title compound as a solid.
- the diastereomeric ratio of the product was determined using chiral high performance liquid chromatography (HPLC) analysis on a Daicel Chiralcel® OD HPLC column to be about 99:1.
- Step E Preparation of 2-bromo-l-[(5i?)-4,5-dihydro-5-phenyl-3-isoxazolyl]ethanone
- reaction mixture was diluted with water (10 mL), and the organic layer was concentrated under reduced pressure and purified by medium-pressure liquid chromatography using 35% of dichloromethane in hexanes as eluant to give 2.6 g of the title compound as a white solid, melting at 31-33 °C.
- the reaction mixture was then concentrated under reduced pressure, diluted with ethyl acetate, washed with water and brine, dried (MgS0 4 ), and concentrated under reduced pressure to give the title product as a pale-yellow foam.
- the sample was dissolved in methyl acetate (2 mL) and allowed to sit at room temperature and then at 0 °C to give 220 mg of colorless crystals melting at 120- 125 °C.
- a second preparation was crystallized from methanol to give large prisms melting at 121-124 °C.
- X is CH.
- X is CH.
- 4-methylthiophenyl NH o 4-trifluoromethylthiophenyl NH o
- 4-methylsulfinylphenyl NH o X is CH.
- X is CH.
- X is CH.
- Table IB is constructed the same as Table 1 A, except that X is N.
- a dash "-" in the (R ) m column means no R 3 substituent is present.
- A is O; X is CH.
- 4-(methoxyethyl)phenyl - cyclopropyl A is O; X is CH.
- Table 2B is constructed the same as Table 2A, except that A is NH and X is CH.
- Table 2C is constructed the same as Table 2 A, except that A is S and X is CH.
- Table 2D is constructed the same as Table 2A, except that A is O and X is N.
- Table 2E is constructed the same as Table 2A, except that A is NH and X is N.
- Table 2F is constructed the same as Table 2A, except that A is S and X is N.
- A is O; X is CH.
- A is O; X is CH.
- A is O; X is CH.
- Table 3B is constructed the same as Table 3A, except that A is NH and X is CH.
- Table 3C is constructed the same as Table 3 A, except that A is S and X is CH.
- Table 3D is constructed the same as Table 3A, except that A is O and X is N.
- Table 3E is constructed the same as Table 3A, except that A is NH and X is N.
- Table 3F is constructed the same as Table 3A, except that A is S and X is N.
- A is O.
- CH G-44 A is O.
- a dash "-" in the (R 2 ) n column means no R 2 substituent is present on ring members other than X.
- the entries in the columns headed by G and (R Y ) q refer to groups defined in Exhibit 2.
- a dash "-" in the (R Y ) q column means no R Y substituent is present.
- Table 4B is constructed the same as Table 4A, except that A is NH.
- Table 4C is constructed the same as Table 4 A, except that A is S.
- the compounds herein, including pharmaceutically acceptable salts can be administered as crystalline or amorphous forms, prodrugs, metabolites, hydrates, solvates, complexes, and tautomers thereof, as well as all isotopically-labelled compounds thereof. They may be administered alone or in combination with one another or with one or more pharmacologically active compounds which are different than the compounds described or specifically named herein, and the pharmaceutically acceptable salts thereof. Generally, one or more these compounds are administered as a pharmaceutical composition (a formulation) in association with one or more pharmaceutically acceptable excipients. The choice of excipients depends on the particular mode of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form, among other things. Useful pharmaceutical compositions and methods for their preparation may be found, for example, in A. R. Gennaro (ed.), Remington: The Science and Practice of Pharmacy (20th ed., 2000).
- compositions comprising a therapeutically effective amount of a compound described herein, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers and/or excipients.
- the compounds herein, and the pharmaceutically acceptable salts thereof can be administered orally.
- Oral administration may involve swallowing in which case the compound enters the bloodstream via the gastrointestinal tract.
- oral administration may involve mucosal administration (e.g., buccal, sublingual, supralingual administration) such that the compound enters the bloodstream through the oral mucosa.
- Formulations suitable for oral administration include solid, semi-solid and liquid systems such as tablets; soft or hard capsules containing multi- or nano-particulates, liquids, or powders; lozenges which may be liquid-filled; chews; gels; fast dispersing dosage forms; films; ovules; sprays; and buccal or mucoadhesive patches.
- Liquid formulations include suspensions; solutions, syrups and elixirs. Such formulations may be employed as fillers in soft or hard capsules (made, for example, from gelatin or hydroxypropyl methylcellulose) and typically comprise a carrier (e.g., water, ethanol, polyethylene glycol, propylene glycol, methylcellulose, or a suitable oil) and one or more emulsifying agents, suspending agents or both. Liquid formulations may also be prepared by the reconstitution of a solid (e.g., from a sachet).
- a carrier e.g., water, ethanol, polyethylene glycol, propylene glycol, methylcellulose, or a suitable oil
- emulsifying agents e.g., suspending agents or both.
- Liquid formulations may also be prepared by the reconstitution of a solid (e.g., from a sachet).
- the compounds herein, and the pharmaceutically acceptable salts thereof, may also be used in fast-dissolving, fast-disintegrating dosage forms such as those described in Liang and Chen, Expert Opinion in Therapeutic Patents 2001, 11, 981-986.
- the active pharmaceutical ingredient may comprise from about 1 to about 80 wt. % of the dosage form or more typically from about 5 to about 60 wt. % of the dosage form.
- tablets may include one or more disintegrants, binders, diluents, surfactants, glidants, lubricants, antioxidants, colorants, flavoring agents, preservatives, and taste-masking agents.
- disintegrants examples include sodium starch glycolate, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, crospovidone, polyvinylpyrrolidone, methyl cellulose, microcrystalline cellulose, ⁇ -Cg alkyl-substituted hydroxypropylcellulose, starch, pregelatinized starch, and sodium alginate.
- the disintegrant will comprise from about 1 to about 25 wt. % or from about 5 to about 20 wt. %of the dosage form.
- Binders are generally used to impart cohesive qualities to a tablet formulation.
- Suitable binders include microcrystalline cellulose, gelatin, sugars, polyethylene glycol, natural and synthetic gums, polyvinylpyrrolidone, pregelatinized starch, hydroxypropylcellulose and hydroxypropylmethylcellulose. Tablets may also contain diluents, such as lactose (monohydrate, spray-dried monohydrate, anhydrous), mannitol, xylitol, dextrose, sucrose, sorbitol, microcrystalline cellulose, starch and dibasic calcium phosphate dihydrate. Tablets may also include surface active agents, such as sodium lauryl sulfate and polysorbate, and glidants such as silicon dioxide and talc.
- diluents such as lactose (monohydrate, spray-dried monohydrate, anhydrous), mannitol, xylitol, dextrose, sucrose, sorbitol, microcrystalline cellulose, starch and dibasic calcium phosphate dihydrate. Tablet
- surface active agents may comprise from about 0.2 to about 5 wt. % of the tablet, and glidants may comprise from about 0.2 about 1 wt. % of the tablet.
- Tablets may also contain lubricants such as magnesium stearate, calcium stearate, zinc stearate, sodium stearyl fumarate, and mixtures of magnesium stearate with sodium lauryl sulfate.
- Lubricants may comprise from about 0.25 about 10 wt. % or from about 0.5 to about 3 wt. % of the tablet. Tablet blends may be compressed directly or by roller compaction to form tablets.
- Tablet blends or portions of blends may alternatively be wet-, dry-, or melt-granulated, melt-congealed, or extruded before tableting. If desired, prior to blending, one or more of the components may be sized by screening or milling or both.
- the final dosage form may comprise one or more layers and may be coated, uncoated, or encapsulated. Exemplary tablets may contain up to about 80 wt. % of API, from about 10 to about 90 wt. % of binder, from about 0 to about 85 wt. % of diluent, from about 2 to about 10 wt. % of disintegrant, and from about 0.25 to about 10 wt. % of lubricant.
- a typical film includes one or more film-forming polymers, binders, solvents, humectants, plasticizers, stabilizers or emulsifiers, viscosity-modifying agents, and solvents.
- film ingredients may include anti-oxidants, colorants, flavorants and flavor enhancers, preservatives, salivary stimulating agents, cooling agents, co-solvents (including oils), emollients, bulking agents, anti-foaming agents, surfactants, and taste-masking agents.
- Some components of the formulation may perform more than one function.
- the amount of API in the film may depend on its solubility. If water soluble, the API would typically comprise from about 1 to about 80 wt. %of the non-solvent components (solutes) in the film or from about 20 to about 50 wt. % of the solutes in the film. A less soluble API may comprise a greater proportion of the composition, typically up to about 88 wt. % of the non-solvent components in the film.
- the film-forming polymer can be selected from natural polysaccharides, proteins, or synthetic hydrocolloids and typically comprises from about 0.01 to about 99 wt. % or from about 30 to about 80 wt. %of the film.
- Film dosage forms are typically prepared by evaporative drying of thin aqueous films coated onto a peelable backing support or paper, which may carried out in a drying oven or tunnel (e.g., in a combined coating-drying apparatus), in lyophilization equipment, or in a vacuum oven.
- Useful solid formulations for oral administration may include immediate release formulations and modified release formulations.
- Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted-, and programmed-release.
- suitable modified release formulations see US Patent No. 6,106,864.
- Other useful release technologies such as high energy dispersions and osmotic and coated particles, see Verma et al, Pharmaceutical Technology On-line 2001 25, 1-14.
- Compounds herein, and the pharmaceutically acceptable salts thereof may also be administered directly into the blood stream, muscle, or an internal organ of the subject.
- Suitable techniques for parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular, intrasynovial, and subcutaneous administration.
- Suitable devices for parenteral administration include needle injectors, including microneedle injectors, needle- free injectors, and infusion devices.
- Parenteral formulations are typically aqueous solutions which may contain excipients such as salts, carbohydrates and buffering agents (e.g., pH of from about 3 to about 9).
- excipients such as salts, carbohydrates and buffering agents (e.g., pH of from about 3 to about 9).
- the compounds herein, and the pharmaceutically acceptable salts thereof may be more suitably formulated as a sterile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile, pyrogen-free water.
- a suitable vehicle such as sterile, pyrogen-free water.
- the preparation of parenteral formulations under sterile conditions may be readily accomplished using standard pharmaceutical techniques.
- solubility of compounds which are used in the preparation of parenteral solutions may be increased through appropriate formulation techniques, such as the incorporation of solubility-enhancing agents.
- Formulations for parenteral administration may be formulated to be immediate or modified release. Modified release formulations include delayed, sustained, pulsed, controlled, targeted, and programmed release.
- compounds herein, and the pharmaceutically acceptable salts thereof may be formulated as a suspension, a solid, a semi-solid, or a thixotropic liquid for administration as an implanted depot providing modified release of the active compound.
- examples of such formulations include drug- coated stents and semi-solids and suspensions comprising drug-loaded poly(DL-lactic- coglycolic)acid (PGLA) microspheres.
- the compounds herein, and the pharmaceutically acceptable salts thereof may also be administered topically, intradermally, or transdermally to the skin or mucosa.
- Typical formulations for this purpose include gels, hydrogels, lotions, solutions, creams, ointments, dusting powders, dressings, foams, films, skin patches, wafers, implants, sponges, fibers, bandages and microemulsions. Liposomes may also be used.
- Typical carriers may include alcohol, water, mineral oil, liquid petrolatum, white petrolatum, glycerin, polyethylene glycol and propylene glycol.
- Topical formulations may also include penetration enhancers. See, e.g., Finnin and Morgan, J. Pharm. Sci.
- Topical administration include delivery by electroporation, iontophoresis, phonophoresis, sonophoresis and microneedle or needle-free injection.
- Formulations for topical administration may be formulated to be immediate or modified release as described above.
- the compounds herein, and the pharmaceutically acceptable salts thereof may also be administered intranasally or by inhalation, typically in the form of a dry powder, an aerosol spray, or nasal drops.
- An inhaler may be used to administer the dry powder, which comprises the API alone, a powder blend of the API and a diluent, such as lactose, or a mixed component particle that includes the API and a phospholipid, such as phosphatidylcholine.
- the powder may include a bioadhesive agent, e.g., chitosan or cyclodextrin.
- a pressurized container, pump, sprayer, atomizer, or nebulizer may be used to generate the aerosol spray from a solution or suspension comprising the API, one or more agents for dispersing, solubilizing, or extending the release of the API (e.g., EtOH with or without water), one or more solvents (e.g., 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoropropane) which serve as a propellant, and an optional surfactant, such as sorbitan trioleate, oleic acid, or an oligolactic acid.
- An atomizer using electrohydrodynamics may be used to produce a fine mist.
- the drug product Prior to use in a dry powder or suspension formulation, the drug product is usually comminuted to a particle size suitable for delivery by inhalation (typically 90% of the particles, based on volume, having a largest dimension less than 5 microns). This may be achieved by any appropriate size reduction method, such as spiral jet milling, fluid bed jet milling, supercritical fluid processing, high pressure homogenization, or spray drying.
- Capsules, blisters and cartridges for use in an inhaler or insufflator maybe formulated to contain a powder mixture of the active compound, a suitable powder base such as lactose or starch, and a performance modifier such as L-Ieucine, mannitol, or magnesium stearate.
- the lactose may be anhydrous or monohydrated.
- Other suitable excipients include dextran, glucose, maltose, sorbitol, xylitol, fructose, sucrose, and trehalose.
- a suitable solution formulation for use in an atomizer using electrohydrodynamics to produce a fine mist may contain from about 1 ⁇ g to about 20 mg of the API per actuation and the actuation volume may vary from about 1 ⁇ ⁇ to about 100 ⁇ .
- a typical formulation may comprise one or more of the compounds herein, or a pharmaceutically acceptable salt thereof, propylene glycol, sterile water, EtOH, and NaCl.
- Formulations for inhaled administration, intranasal administration, or both may be formulated to be immediate or modified release using, for example, PGLA.
- Suitable flavors, such as menthol and levomenthol, or sweeteners, such as saccharin or sodium saccharin, may be added to formulations intended for inhaled/intranasal administration.
- the dosage unit is determined by means of a valve that delivers a metered amount.
- Units are typically arranged to administer a metered dose or "puff containing from about 10 ⁇ g to about 1000 ⁇ g of the API.
- the overall daily dose will typically range from about 100 ⁇ g to about 10 mg which may be administered in a single dose or, more usually, as divided doses throughout the day.
- the active compounds may be administered rectally or vaginally, e.g., in the form of a suppository, pessary, or enema. Cocoa butter is a traditional suppository base, but various alternatives may be used as appropriate.
- Formulations for rectal or vaginal administration may be formulated to be immediate or modified release as described above.
- the compounds herein, and the pharmaceutically acceptable salts thereof may also be administered directly to the eye or ear, typically in the form of drops of a micronized suspension or solution in isotonic, pH-adjusted, sterile saline.
- Other formulations suitable for ocular and aural administration include ointments, gels, biodegradable implants (e.g., absorbable gel sponges, collagen), non-biodegradable implants (e.g., silicone), wafers, lenses, and particulate or vesicular systems, such as niosomes or liposomes.
- the formulation may include one or more polymers and a preservative, such as benzalkonium chloride.
- Typical polymers include crossed-linked polyacrylic acid, polyvinylalcohol, hyaluronic acid, cellulosic polymers (e.g., hydroxypropylmethylcellulose, hydroxyethylcellulose, methyl cellulose), and heteropolysaccharide polymers (e.g., gelan gum). Such formulations may also be delivered by iontophoresis. Formulations for ocular or aural administration may be formulated to be immediate or modified release as described above.
- the compounds herein, and the pharmaceutically acceptable salts thereof, and their pharmaceutically active complexes, solvates and hydrates may be combined with one another or with one or more other active pharmaceutically active compounds to treat various diseases, conditions and disorders.
- the active compounds may be combined in a single dosage form as described above or may be provided in the form of a kit which is suitable for co-administration of the compositions.
- the kit comprises (1) two or more different pharmaceutical compositions, at least one of which contains a compound of Formula 1; and (2) a device for separately retaining the two pharmaceutical compositions, such as a divided bottle or a divided foil packet.
- An example of such a kit is the familiar blister pack used for the packaging of tablets or capsules.
- the kit is suitable for administering different types of dosage forms (e.g., oral and parenteral) or for administering different pharmaceutical compositions at separate dosing intervals, or for titrating the different pharmaceutical compositions against one another.
- the kit typically comprises directions for administration and may be provided with a memory aid.
- the total daily dose of the claimed and disclosed compounds is typically in the range of about 0.1 mg to about 3000 mg depending on the route of administration.
- oral administration may require a total daily dose of from about 1 mg to about 3000 mg
- an intravenous dose may only require a total daily dose of from about 0.1 mg to about 300 mg.
- the total daily dose may be administered in single or divided doses and, at the physician's discretion, may fall outside of the typical ranges given above. Although these dosages are based on an average human subject having a mass of about 60 kg to about 70 kg, the physician will be able to determine the appropriate dose for a patient (e.g., an infant) whose mass falls outside of this weight range.
- the claimed and disclosed compounds may be combined with one or more other pharmacologically active compounds for the treatment of one or more related disorders
- the pharmacologically active compounds can be selected from: (1) an opioid analgesic, e.g., morphine, fentanyl, codeine, etc.; (2) a nonsteroidal antiinflammatory drug (NSAID), e.g., acetaminophen, aspirin, diclofenac, etodolac, ibuprofen, naproxen, etc.; (3) a barbiturate sedative, e.g., pentobarbital; (4) a benzodiazepine having a sedative action, e.g., diazepam, lorazepam, etc.; (5) an HI antagonist having a sedative action, e.g., diphenhydramine; (6) a sedative such as glutethimide, meprobamate, methaqualone or dichloralphenazone;
- a tricyclic antidepressant e.g., desipramine, imipramine, amitriptyline or nortriptyline;
- an anticonvulsant e.g., carbamazepine, lamotrigine, topiratmate or valproate
- a tachykinin (NK) antagonist particularly an NK-3, NK-2 or NK-1 antagonist
- a muscarinic antagonist e.g., oxybutynin, tolterodine, etc.
- a COX-2 selective inhibitor e.g., celecoxib, valdecoxib, etc.
- a coal-tar analgesic in particular paracetamol
- a neuroleptic such as haloperidol, clozapine, olanzapine, risperidone, ziprasidone, or Miraxion®
- a vanilloid receptor (VR1; also known as transient receptor potential channel, TRPV1) agonist e.g., resinferatoxin
- antagonist e.g., capsazepine
- iNOS inducible nitricoxide synthase
- FAAH Expression and Purification - recombinant human FAAH was expressed in truncated form, in which the transmembrane (TM) portion of the enzyme was removed from the N-terminal (amino acids 1-33), and then heterologously expressed as a MBP (maltose- binding protein) fusion protein in E. coli ( ⁇ - ⁇ -FAAH) similar to the procedure described by Labar, G. et al. Amino acids 2008, 34, 127-133. The region of the gene corresponding to amino acids 34 to 579 was cloned into pMAL-c4x (New England BioLabs, Inc.) using EcoRl and Sail restriction sites. E.
- coli T7 Express cells containing the FAAH constructs, were used for expression of protein by induction with IPTG (isopropyl-P-D- thiogalactopyranoside) (100 ⁇ ) overnight at room temperature in Lennox Broth with 0.2% glucose. After harvest, the cells were resuspended in 20 mM Hepes buffer (pH 7.4) containing 200 mM NaCl, 2mM DTT (dithiothreitol). The cell suspension was lysed by sonication, and the cell debris removed by centrifugation. The soluble extract was adjusted to 2.5 mg/mL protein, and the FAAH fusion protein (-105 kDa) loaded onto a 5 mL column of amylose affinity resin.
- IPTG isopropyl-P-D- thiogalactopyranoside
- the enzyme was eluted using 15 mM maltose as per manufacturer's (New England BioLabs, Inc.) instruction. Fractions containing FAAH were concentrated and further purified using SephacrylTM SI 00 (HIPrepTM 26/60, GE Healthcare, Inc.) chromatography. Fractions enriched in FAAH were pooled, concentrated, and made 10% in glycerol then stored at -80°C until use. All column chromatography steps used the Hepes buffer described above.
- FAAH assay - Enzyme activity was measured using the fluorogenic substrate, decanoyl 7-amino-4-methylcoumarin (D-AMC) as described by Kage, K.L. et al. J. of Neuroscience Methods 2007, 161, 47-54. Briefly, the assay buffer consisted of 125 mM Tris-CL, 1 mM EDTA, and 0.1% BSA (pH 8.0). D-AMC was used at final concentration of 5 ⁇ in all assays. Reactions were carried out in black 96-well microplates (Costar, Inc) using a SpectraMax GeminiTM (Molecular Devices, Inc.) fluorescence plate reader in a reaction volume of 200 per well at 37 °C.
- D-AMC decanoyl 7-amino-4-methylcoumarin
- the assay reaction mixture contained enzyme, 100 uM substrate, 0.125 M TrisCl, and 0.2 mM EDTA, pH 8.0 in a total volume of 200 ⁇ . Reactions were started by the addition of substrate. Control reactions give linear reaction rates (20 to 50 mOD/min) over at least 5 min. Table B describes IC50 results for a series of selected compounds. All compounds tested showed at most, only slight inhibition of pancreatic elastase at the highest concentration tested (10 ⁇ ). Several compounds should some level of inhibition of liver esterase, but IC 50 values were orders of magnitude less potent compared to FAAH inhibition. These results indicated a high degree of specificity for FAAH inhibition by these compounds.
- Analgesic Potential of FAAH Inhibitors by Tail Immersion Assy in Mice The analgesic potential of Compounds 1, 11, 61 and 49 were determined by tail immersion assay.
- Anandamide a brain lipid involved in natural analgesic response
- OL-135 alone an inhibitor of fatty acid amide hydrolase that metabolizes anandamide
- Two vehicle controls (2:2: 16 DMSO:Alkamuls:saline and 1 : 1 : 18 EtOH:Alkamuls: saline) were also evaluated.
- Previous research indicates that administration of anandamide alone is largely ineffective in causing hypothermia or analgesia.
- Analgesia was evaluated in female mice by immersing approximately 3.5 cm of each tail into water that was maintained at 52 +/- 1 °C for a maximum of 10 seconds (sec). The length of time until the animal removed its tail from the water or made a significant tail movement was measured. If the response time was less than 5 sec, a second trial was conducted. The test data are shown in Table C.
- a preliminary study was conducted to determine the optimal time interval between administration of OL-135 or the test substances and the administration of anandamide, and to determine the time interval between treatment with anandamide and conducting the tail immersion assay. Based on the results of the preliminary study, the time interval between administration of the test substances and anandamide was established as 40 minutes. In addition, the time interval between administration of anandamide and conducting the tail immersion assay was established to be 40 minutes.
- Vehicle 1 4.0 (1.6) 4.6 (1.6) -1.0% (56.8%)
- Vehicle 2 7.0 (2.4) 5.2 (1.7) -23.9% (31.1%)
- ⁇ is percent of the maximum possible effect (test-baseline)/(10-baseline)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012543305A JP2013513615A (ja) | 2009-12-11 | 2010-12-10 | 脂肪酸アミドヒドロラーゼのアゾ環状阻害薬 |
US13/515,010 US20130045948A1 (en) | 2009-12-11 | 2010-12-10 | Azocyclic inhibitors of fatty acid amide hydrolase |
CA2780905A CA2780905A1 (fr) | 2009-12-11 | 2010-12-10 | Inhibiteurs azocycliques de l'hydrolase des amides d'acides gras |
EP10795166A EP2509978A1 (fr) | 2009-12-11 | 2010-12-10 | Inhibiteurs azocycliques de l'hydrolase des amides d'acides gras |
CN2010800561576A CN102652135A (zh) | 2009-12-11 | 2010-12-10 | 脂肪酸酰胺水解酶的含氮杂环抑制剂 |
AU2010328049A AU2010328049A1 (en) | 2009-12-11 | 2010-12-10 | Azocyclic inhibitors of fatty acid amide hydrolase |
BR112012013801A BR112012013801A2 (pt) | 2009-12-11 | 2010-12-10 | composto,método para inibir a atividade de hidrolase de amida de ácido graxo em um indivíduo,composição farmacêutica e método para tratar um individuo com dor |
MX2012006490A MX2012006490A (es) | 2009-12-11 | 2010-12-10 | Inhibidores azociclicos de hidrolasa de amidas de acidos grasos. |
IL219659A IL219659A0 (en) | 2009-12-11 | 2012-05-08 | Azocyclic inhibitors of fatty acid amide hydrolase |
ZA2012/03371A ZA201203371B (en) | 2009-12-11 | 2012-05-09 | Azocyclic inhibitors of fatty acid amide hydrolase |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28560009P | 2009-12-11 | 2009-12-11 | |
US61/285,600 | 2009-12-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011072207A1 true WO2011072207A1 (fr) | 2011-06-16 |
Family
ID=43478289
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/059850 WO2011072207A1 (fr) | 2009-12-11 | 2010-12-10 | Inhibiteurs azocycliques de l'hydrolase des amides d'acides gras |
Country Status (12)
Country | Link |
---|---|
US (1) | US20130045948A1 (fr) |
EP (1) | EP2509978A1 (fr) |
JP (1) | JP2013513615A (fr) |
KR (1) | KR20120093425A (fr) |
CN (1) | CN102652135A (fr) |
AU (1) | AU2010328049A1 (fr) |
BR (1) | BR112012013801A2 (fr) |
CA (1) | CA2780905A1 (fr) |
IL (1) | IL219659A0 (fr) |
MX (1) | MX2012006490A (fr) |
WO (1) | WO2011072207A1 (fr) |
ZA (1) | ZA201203371B (fr) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013098229A2 (fr) | 2011-12-27 | 2013-07-04 | Bayer Intellectual Property Gmbh | Dérivés d'hétéroarylpipéridine et d'hétéroarylpipérazine utilisés comme fongicides |
WO2015144571A1 (fr) | 2014-03-24 | 2015-10-01 | Bayer Cropscience Ag | Dérivés phénylpipéridinecarboxamide utiles en tant que fongicides |
JP2016128479A (ja) * | 2010-08-25 | 2016-07-14 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 殺菌剤としてのヘテロアリールピペリジンおよび−ピペラジン誘導体 |
WO2016182900A1 (fr) * | 2015-05-08 | 2016-11-17 | Vertellus Specialties, Inc. | Procédés pour convertir des carboxamides en thiocarboxamides |
US9790182B2 (en) | 2014-06-11 | 2017-10-17 | Bayer Cropscience Aktiengesellschaft | Preparation of piperidine-4-carbothioamide |
US10093626B2 (en) | 2015-03-05 | 2018-10-09 | Bayer Cropscience Aktiengesellschaft | Process for preparing piperidine-4-carbothioamide hydrochloride |
US10189799B2 (en) | 2015-03-05 | 2019-01-29 | Bayer Cropscience Aktiengesellschaft | Process for preparing substituted phenylisoxazoline derivatives |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX352307B (es) * | 2011-02-01 | 2017-11-17 | Bayer Ip Gmbh | Derivados de heteroarilpiperidina y -piperazina como fungicidas. |
US9717243B2 (en) * | 2013-06-24 | 2017-08-01 | Bayer Cropscience Aktiengesellschaft | Piperidinecarboxylic acid derivatives as fungicides |
US10336742B2 (en) * | 2014-05-28 | 2019-07-02 | Bayer Cropscience Aktiengesellschaft | Process for preparing thiazole derivatives |
CN107602550B (zh) * | 2017-10-25 | 2018-10-23 | 磐安县宸熙工艺品有限公司 | 一种脂肪酰胺水解酶抑制剂及其制备方法 |
CN110804048A (zh) * | 2019-11-08 | 2020-02-18 | 暨南大学 | 恶唑酮类化合物及其应用、faah的正电子药物 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3557089A (en) | 1968-12-27 | 1971-01-19 | Du Pont | Preparation of l-(carbamoyl)-n-(carbamoyloxy) thioformimidates from acetoacetamides |
EP0696581A2 (fr) | 1994-08-12 | 1996-02-14 | Fine Organics Limited | Préparation de thioamides |
US6106864A (en) | 1995-09-15 | 2000-08-22 | Pfizer Inc. | Pharmaceutical formulations containing darifenacin |
WO2007005510A1 (fr) * | 2005-06-30 | 2007-01-11 | Janssen Pharmaceutica N.V. | Urees n-heteroarylpiperazinyle en tant que modulateurs de l'hydrolase de l'amide d'acide gras |
EP2065369A1 (fr) * | 2006-08-23 | 2009-06-03 | Astellas Pharma Inc. | Compose d'uree ou sel dudit compose |
WO2009094445A2 (fr) * | 2008-01-25 | 2009-07-30 | E. I. Du Pont De Nemours And Company | Composés hétérocycliques fongicides |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200738701A (en) * | 2005-07-26 | 2007-10-16 | Du Pont | Fungicidal carboxamides |
-
2010
- 2010-12-10 US US13/515,010 patent/US20130045948A1/en not_active Abandoned
- 2010-12-10 BR BR112012013801A patent/BR112012013801A2/pt not_active IP Right Cessation
- 2010-12-10 EP EP10795166A patent/EP2509978A1/fr not_active Withdrawn
- 2010-12-10 CA CA2780905A patent/CA2780905A1/fr not_active Abandoned
- 2010-12-10 CN CN2010800561576A patent/CN102652135A/zh active Pending
- 2010-12-10 JP JP2012543305A patent/JP2013513615A/ja active Pending
- 2010-12-10 KR KR1020127017873A patent/KR20120093425A/ko not_active Application Discontinuation
- 2010-12-10 WO PCT/US2010/059850 patent/WO2011072207A1/fr active Application Filing
- 2010-12-10 MX MX2012006490A patent/MX2012006490A/es not_active Application Discontinuation
- 2010-12-10 AU AU2010328049A patent/AU2010328049A1/en not_active Abandoned
-
2012
- 2012-05-08 IL IL219659A patent/IL219659A0/en unknown
- 2012-05-09 ZA ZA2012/03371A patent/ZA201203371B/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3557089A (en) | 1968-12-27 | 1971-01-19 | Du Pont | Preparation of l-(carbamoyl)-n-(carbamoyloxy) thioformimidates from acetoacetamides |
EP0696581A2 (fr) | 1994-08-12 | 1996-02-14 | Fine Organics Limited | Préparation de thioamides |
US6106864A (en) | 1995-09-15 | 2000-08-22 | Pfizer Inc. | Pharmaceutical formulations containing darifenacin |
WO2007005510A1 (fr) * | 2005-06-30 | 2007-01-11 | Janssen Pharmaceutica N.V. | Urees n-heteroarylpiperazinyle en tant que modulateurs de l'hydrolase de l'amide d'acide gras |
EP2065369A1 (fr) * | 2006-08-23 | 2009-06-03 | Astellas Pharma Inc. | Compose d'uree ou sel dudit compose |
WO2009094445A2 (fr) * | 2008-01-25 | 2009-07-30 | E. I. Du Pont De Nemours And Company | Composés hétérocycliques fongicides |
Non-Patent Citations (45)
Title |
---|
"Bioreversible Carriers in Drug Design", 1987 |
"Comprehensive Heterocyclic Chemistry II", 1996, PERGAMON PRESS |
"Comprehensive Heterocyclic Chemistry II", vol. 2-4, 1996, PERGAMON PRESS |
"Comprehensive Heterocyclic Chemistry", 1984, PERGAMON PRESS |
"Comprehensive Heterocyclic Chemistry", vol. 4-6, 1984, PERGAMON PRESS |
"Pharmaceutical Dosage Forms: Tablets", vol. 1-3, 1990 |
"Remington: The Science and Practice of Pharmacy", 2000 |
"The Chemistry of Heterocyclic Compounds", WILEY |
A. H. LICHTMAN ET AL., J. PHARMACOL. EXP. THER., vol. 311, no. 2, 2004, pages 441 - 448 |
A. H. LICHTMAN, THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 311, 2004, pages 441 - 448 |
A. JAYAMANNE ET AL., BR. J. PHARMACOL., vol. 147, no. 3, 2006, pages 281 - 288 |
D. K. PARIKH; C. K. PARIKH: "Handbook of Pharmaceutical Granulation Technology", vol. 81, 1997 |
D. PIOMELLI ET AL., PROC. NATL. ACAD. SCI., vol. 102, no. 51, 2005, pages 18620 - 18625 |
FINNIN; MORGAN, J. PHARM. SCI., vol. 88, 1999, pages 955 - 958 |
G. W. H. CHEESEMAN; E. S. G. WERSTIUK: "Advances in Heterocyclic Chemistry", vol. 22, ACADEMIC PRESS, pages: 390 - 392 |
GREENE, T. W.; WUTS, P. G.: "M. Protective Groups in Organic Synthesis", 1991, WILEY |
GRENNAN; JAYSON: "Textbook of Pain", 1994, pages: 397 - 407 |
HIGUCHI; V. STELLA: "Pro-drugs as Novel Delivery Systems", 1975, ACS SYMPOSIUM SERIES |
HOUGE; MERSFELDER, NN PHARMACOTHER., vol. 36, 2002, pages 679 - 686 |
J. K. HALEBLIAN, J. PHARM. SCI., vol. 64, 1975, pages 1269 - 88 |
J. L. COLLINS ET AL., J. MED. CHEM., vol. 41, 1998, pages 5037 - 5054 |
KAGE, K.L. ET AL., J. OF NEUROSCIENCE METHODS, vol. 161, 2007, pages 47 - 54 |
KANEMASA ET AL., TETRAHEDRON, vol. 56, 2000, pages 1057 - 1064 |
LABAR, G. ET AL., AMINO ACIDS, vol. 34, 2008, pages 127 - 133 |
LEE, SYNTHESIS, vol. 6, 1982, pages 508 - 509 |
LIANG; CHEN, EXPERT OPINION IN THERAPEUTIC PATENTS, vol. 11, 2001, pages 981 - 986 |
M. NAKAMURA ET AL., SYNLETT, 2005, pages 1794 - 1798 |
M. R. GRIMMETT; B. R. T. KEENE: "Advances in Heterocyclic Chemistry", vol. 43, ACADEMIC PRESS, pages: 149 - 161 |
M. TISLER; B. STANOVNIK: "Advances in Heterocyclic Chemistry", vol. 9, ACADEMIC PRESS, pages: 285 - 291 |
M. TISLER; B. STANOVNIK: "Comprehensive Heterocyclic Chemistry", vol. 3, PERGAMON PRESS, pages: 18 - 20 |
MCCARTHY ET AL.: "Textbook of Pain", 1994, pages: 387 - 395 |
MCYCR, TEXTBOOK OF PAIN, 1994, pages 13 - 44 |
MILLAN, PROG. NEUROBIOL., vol. 57, 1999, pages 1 - 164 |
O. ALMARSSON; M. J. ZAWOROTKO, CHEM. COMMUN., vol. 17, 2004, pages 1889 - 1896 |
S. BELLOTTE, SYNLETT, 1998, pages 379 - 380 |
S. KATHURIA ET AL., NATURE MED., vol. 9, no. 1, 2003, pages 76 - 81 |
S. M. BERGE ET AL.: "Pharmaceutical Salts", J. PHARM. SCI., vol. 66, 1977, pages 1 - 19 |
STAHL; WERMUTH: "Handbook of Pharmaceutical Salts: Properties, Selection, and Use", 2002 |
T. L. GILCHRIST: "Comprehensive Organic Synthesis", vol. 7, PERGAMON PRESS, pages: 748 - 750 |
T. W. GREENE; P. G. M. WUTS: "Protective Groups in Organic Synthesis", 1991, WILEY |
VERMA ET AL., PHARMACEUTICAL TECHNOLOGY ON-LINE, vol. 25, 2001, pages 1 - 14 |
WOOLF; DECOSTERD, PAIN SUPP, vol. 6, 1999, pages S141 - S 147 |
WOOLF; MANNION, LANCET, vol. 353, 1999, pages 1959 - 1964 |
WOOLF; SALTER, SCIENCE, vol. 288, 2000, pages 1765 - 1768 |
Y. NISHIYAMA ET AL., J. ORG. CHEM., vol. 70, 2005, pages 2551 - 2554 |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2609094B1 (fr) * | 2010-08-25 | 2018-05-30 | Bayer Intellectual Property GmbH | Dérivés hétéroarylpipéridine et hétéroarylpipérazine en tant que fongicides |
JP2016128479A (ja) * | 2010-08-25 | 2016-07-14 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 殺菌剤としてのヘテロアリールピペリジンおよび−ピペラジン誘導体 |
EP2921492A1 (fr) | 2011-12-27 | 2015-09-23 | Bayer Intellectual Property GmbH | Dérivés d'hétéroarylpipéridine et -pipérazine |
EP2921485A1 (fr) | 2011-12-27 | 2015-09-23 | Bayer Intellectual Property GmbH | Dérivés d'isoxazole |
EP2921481A1 (fr) | 2011-12-27 | 2015-09-23 | Bayer Intellectual Property GmbH | Dérivés d'acide de 4-piperidine |
EP2921493A1 (fr) | 2011-12-27 | 2015-09-23 | Bayer Intellectual Property GmbH | Dérivés d'hétéroarylpipéridine et -pipérazine |
EP2921491A1 (fr) | 2011-12-27 | 2015-09-23 | Bayer Intellectual Property GmbH | Produits intermédiaires pour la production des dérivés d'hétéroarylpipéridine et -pipérazine comme fongicides |
EP2921484A1 (fr) | 2011-12-27 | 2015-09-23 | Bayer Intellectual Property GmbH | Dérivés d'oxazole |
EP2921495A1 (fr) | 2011-12-27 | 2015-09-23 | Bayer Intellectual Property GmbH | Dérivés d'hétéroarylpipéridine et -pipérazine comme fongicides |
EP2921494A1 (fr) | 2011-12-27 | 2015-09-23 | Bayer Intellectual Property GmbH | Dérivés d'hétéroarylpipéridine et -pipérazine |
WO2013098229A2 (fr) | 2011-12-27 | 2013-07-04 | Bayer Intellectual Property Gmbh | Dérivés d'hétéroarylpipéridine et d'hétéroarylpipérazine utilisés comme fongicides |
KR20140108702A (ko) * | 2011-12-27 | 2014-09-12 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | 살진균제로서의 헤테로아릴피페리딘 및 피페라진 유도체 |
KR102015968B1 (ko) | 2011-12-27 | 2019-08-29 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | 살진균제로서의 헤테로아릴피페리딘 및 피페라진 유도체 |
WO2015144571A1 (fr) | 2014-03-24 | 2015-10-01 | Bayer Cropscience Ag | Dérivés phénylpipéridinecarboxamide utiles en tant que fongicides |
US9790182B2 (en) | 2014-06-11 | 2017-10-17 | Bayer Cropscience Aktiengesellschaft | Preparation of piperidine-4-carbothioamide |
US10093626B2 (en) | 2015-03-05 | 2018-10-09 | Bayer Cropscience Aktiengesellschaft | Process for preparing piperidine-4-carbothioamide hydrochloride |
US10189799B2 (en) | 2015-03-05 | 2019-01-29 | Bayer Cropscience Aktiengesellschaft | Process for preparing substituted phenylisoxazoline derivatives |
US10604495B2 (en) | 2015-03-05 | 2020-03-31 | Bayer Cropscience Aktiengesellschaft | Process for preparing substituted phenylisoxazoline derivatives |
WO2016182900A1 (fr) * | 2015-05-08 | 2016-11-17 | Vertellus Specialties, Inc. | Procédés pour convertir des carboxamides en thiocarboxamides |
US10414723B2 (en) | 2015-05-08 | 2019-09-17 | Vertellus Holdings Llc | Processes for converting carboxamides to thiocarboxamides |
Also Published As
Publication number | Publication date |
---|---|
JP2013513615A (ja) | 2013-04-22 |
CA2780905A1 (fr) | 2011-06-16 |
IL219659A0 (en) | 2012-07-31 |
AU2010328049A1 (en) | 2012-05-31 |
US20130045948A1 (en) | 2013-02-21 |
EP2509978A1 (fr) | 2012-10-17 |
ZA201203371B (en) | 2013-08-28 |
CN102652135A (zh) | 2012-08-29 |
KR20120093425A (ko) | 2012-08-22 |
BR112012013801A2 (pt) | 2019-09-24 |
MX2012006490A (es) | 2012-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20130045948A1 (en) | Azocyclic inhibitors of fatty acid amide hydrolase | |
EP2590957B1 (fr) | N-sulfonylbenzamides comme inhibiteurs des canaux sodiques voltage-dépendant | |
US8772343B2 (en) | Chemical compounds | |
CA2860553C (fr) | N-aminosulfonylbenzamides | |
DK2385938T3 (en) | Sulfonamidderivater | |
EP2791108B1 (fr) | Dérivés sulfonamides | |
EP2593431B1 (fr) | N-sulfonylbenzamides comme inhibiteurs des canaux sodiques voltage-dépendant | |
CA2804173C (fr) | Inhibiteurs de nav1.7 de type sulfonamide | |
CA2850925C (fr) | Derives de (4-phenylimidazol-2-yl) ethylamine utiles comme modulateurs de canal de sodium | |
AU2007311591B2 (en) | Biaryl ether urea compounds | |
US20110053982A1 (en) | Ether benzylidene piperidine 5-membered aryl carboxamide compounds useful as faah inhibitors | |
US9163021B2 (en) | Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors | |
US20150250785A1 (en) | Tropomyosin-Related Kinase Inhibitors | |
WO2013093688A1 (fr) | Dérivés sulfonamides et leur utilisation en tant qu'inhibiteurs de vgsc |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080056157.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10795166 Country of ref document: EP Kind code of ref document: A1 |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10795166 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 219659 Country of ref document: IL Ref document number: 2010328049 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2780905 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4226/DELNP/2012 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010795166 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2010328049 Country of ref document: AU Date of ref document: 20101210 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2012/006490 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012543305 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20127017873 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13515010 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012013801 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012013801 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120608 |